

## Supporting Information

### Phosphine-Controlled Divergent Reactions of MBH-Carbonates with Azaheptafulvenes: Access to *o*-Anilinyll diene and Benzazepine Derivatives

Wei Hao,<sup>a</sup> Yiwen Zhang,<sup>a</sup> Xiao Han,<sup>a</sup> Zhen Wang,<sup>\*b</sup> and Weijun Yao <sup>\* a</sup>

<sup>a</sup> School of Chemistry and Chemical Engineering, Zhejiang Sci-Tech University, Hangzhou, 310018, P. R. of China.

<sup>b</sup> School of Pharmaceutical Sciences and Chongqing Key Laboratory of Natural Drug Research, Chongqing University, Chongqing, 401331, P. R. of China.

\* Orgywj@zstu.edu.cn; wangz1114@cqu.edu.cn.

#### Table of contents


A. General information	S1
B. Synthesis of MBH-carbonates <b>2</b>	S1
C. Optimization of the cascade reaction for <b>3aa</b>	S4
D. General procedure for synthesis of <i>o</i> -aminophenyl diene <b>3</b>	S5
E. Analytic data for the products <b>3</b>	S5
F. General procedure for synthesis of <b>4</b>	S18
G. Analytic data for the products <b>4</b>	S18
H. Gram-scale synthesis of <b>4aa</b>	S29
I. Transformation of the product <b>4aa</b>	S30
J. X-Ray crystallographic analysis	S31
K. References	S34
L. NMR Spectra	S35

## A. General information

Unless otherwise specified, all reactions were carried out with dry solvents in anhydrous conditions. All solvents were dried by activated molecular sieve (3 Å). All chemicals were used without further purification as commercially available unless otherwise noted. Thin-layer chromatography (TLC) was performed on silica gel plates (60F-254) using UV-light (254 and 365 nm). Flash chromatography was conducted on silica gel (200–300 mesh). <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AMX400 (400 MHz) spectrometer. Chemical shifts were reported in parts per million (ppm). High resolution mass spectra (HRMS) were recorded on a Waters TOF MS GCT Premier using ESI ionization. Petroleum ether (PE) refers to the fraction with boiling point in the range 60 – 90 °C. Troponimines **1** were prepared according to the literature procedure [1].

## B. Synthesis of Morita-Baylis-Hillman carbonates


Morita-Baylis-Hillman carbonates **2a**, **2b**, **2d–2p**, **2r–2u**, **2w** and **2y** are known compounds and the characterization data are in agreement with those reported in the literature. The new compounds **2c**, **2q**, **2v** and **2x** were prepared by following the reported literature procedure.



**Step1:** To the neat mixture of aldehyde **S1** (1.0 equiv.) and acrylate (4.0 equiv.) was added DABCO (1.0 equiv.), then the resulting slurry was stirred vigorously at room temperature. After specified time, the reaction mixture was diluted with DCM. Then the solution was washed with 4 N aqueous HCl, followed by saturated  $\text{NaHCO}_3$  solution and brine. The organic layer was dried over anhydrous  $\text{Na}_2\text{SO}_4$ , filtered and concentrated in vacuum to get the crude product that was purified by flash column chromatography to give Morita-Baylis-Hillman alcohols.


**Step2:** The solution of Morita-Baylis-Hillman alcohols (1.0 equiv.) and DMAP (10 mol%) in DCM (0.6 M) was stirred at 0 °C for 10 minutes. To the cooled solution, a DCM solution of  $(\text{Boc})_2\text{O}$  was then added dropwise (1.1 equiv.) at 0 °C. The resulting solution was stirred at room temperature for 2 h and then stirred at room temperature overnight. Subsequently, the solvent was removed in vacuo and the crude mixture was purified by column chromatography to afford pure Morita-Baylis-Hillman carbonates **2**.

***Isobutyl 2-(((tert-butoxycarbonyl)oxy)(phenyl)methyl)acrylate (2c)***




The title compound was prepared according to the general procedure to afford **2c** (72% yield) as a colorless oil. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.44 – 7.37 (m, 2H), 7.37 – 7.28 (m, 4H), 6.48 (d, *J* = 3.7 Hz, 1H), 6.44 (d, *J* = 3.2 Hz, 1H), 5.90 (d, *J* = 3.3 Hz, 1H), 3.95 – 3.82 (m, 2H), 1.94 – 1.84 (m, 1H), 1.46 (d, *J* = 2.7 Hz, 9H), 0.86 (dd, *J* = 6.6, 3.0 Hz, 6H). **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ 164.9, 152.3, 139.7, 137.5, 128.4, 127.9, 127.7, 125.8, 82.5, 75.8, 71.0, 27.7, 27.6, 19.0. **IR** (KBr): ν 2969, 2875, 1747, 1725, 1631, 1277, 1254, 1159, 1086, 882, 701 cm<sup>-1</sup>; **HRMS** (ESI): *m/z* calcd for C<sub>20</sub>H<sub>24</sub>NO<sub>5</sub> [M+H]<sup>+</sup> = 335.1853, found = 335.1856.

***Ethyl 2-(((tert-butoxycarbonyl)oxy)(2-nitrophenyl)methyl)acrylate (2q)***




The title compound was prepared according to the general procedure to afford **2q** (68% yield) as a white solid. M.p. 90.6 – 93.7 °C; **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 8.04 (d, *J* = 8.2 Hz, 1H), 7.68 – 7.62 (m, 2H), 7.50 (ddd, *J* = 8.5, 5.9, 2.8 Hz, 1H), 7.16 (s, 1H), 6.43 (s, 1H), 5.53 (s, 1H), 4.20 (qd, *J* = 7.2, 2.3 Hz, 2H), 1.46 (s, 9H), 1.24 (t, *J* = 7.1 Hz, 3H). **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ 164.6, 152.0, 147.9, 138.7, 133.5, 133.3, 129.2, 128.6, 127.9, 125.1, 83.2, 71.1, 61.3, 27.7, 14.0. **IR** (KBr): ν 2927, 2856, 1741, 1713, 1586, 1465, 1383, 1353, 1304, 1152, 1102, 954, 736 cm<sup>-1</sup>. **HRMS** (ESI): *m/z* calcd for C<sub>20</sub>H<sub>24</sub>NO<sub>5</sub> [M+H]<sup>+</sup> = 352.1391, found = 352.1401.

***Ethyl 2-(((tert-butoxycarbonyl)oxy)(naphthalen-1-yl)methyl)acrylate (2v)***



The title compound was prepared according to the general procedure to afford **2v** (57% yield) as a pale green solid. M.p. 43.6 – 55.3 °C; **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 8.07 (d, *J* = 8.3 Hz, 1H), 7.87 (d, *J* = 7.9 Hz, 1H), 7.83 (d, *J* = 8.2 Hz, 1H), 7.60 – 7.42 (m, 4H), 7.34 (s, 1H), 6.47 (s, 1H), 5.72 (s, 1H), 4.18 (q, *J* = 7.4, 2H), 1.47 (s, 9H), 1.19 (t, *J* = 7.1 Hz, 3H). **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ 165.2, 152.6, 139.4, 133.8, 133.3, 130.9, 129.2, 128.7, 127.6, 126.5, 125.8, 125.2, 123.5, 82.7, 72.4, 61.0, 27.7, 14.0. **IR** (KBr): ν 2815, 1740, 1719, 1597, 1352, 1277, 1253, 1157, 1088, 884, 777 cm<sup>-1</sup>; **HRMS** (ESI): *m/z* calcd for C<sub>20</sub>H<sub>24</sub>NO<sub>5</sub> [M+H]<sup>+</sup> = 357.1697, found = 357.1692.


**Ethyl 2-(((tert-butoxycarbonyl)oxy)(quinolin-3-yl)methyl)acrylate (2x)**



The title compound was prepared according to the general procedure to afford **2x** (56% yield) as green viscous oil. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 8.95 (d, *J* = 2.2 Hz, 1H), 8.17 (d, *J* = 2.3 Hz, 1H), 8.09 (d, *J* = 8.5 Hz, 1H), 7.81 (d, *J* = 8.2 Hz, 1H), 7.71 (ddd, *J* = 8.4, 6.9, 1.5 Hz, 1H), 7.58 – 7.50 (m, 1H), 6.67 (s, 1H), 6.50 (s, 1H), 6.08 (s, 1H), 4.13 (q, *J* = 7.2 Hz, 2H), 1.45 (s, 9H), 1.21 (t, *J* = 7.2 Hz, 3H). **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ 164.5, 152.2, 150.2, 147.9, 139.0, 135.0, 130.6, 129.9, 129.2, 128.0, 127.5, 126.9, 125.9, 83.1, 73.9, 61.1, 27.7, 14.0. **IR** (KBr): ν 2832, 1747, 1716, 1631, 1364, 1276, 1254, 1157, 1088, 777 cm<sup>-1</sup>; **HRMS** (ESI): *m/z* calcd for C<sub>20</sub>H<sub>24</sub>NO<sub>5</sub> [M+H]<sup>+</sup> = 358.1649, found = 358.1662.

## C. Optimization of the cascade reaction for **3aa**


Table 1. Optimization of the cascade reaction for **3aa**<sup>a</sup>



Entry	Catalyst	Solvent	Temp. (°C)	Time (h)	Proportion <sup>b</sup> ( <b>3aa/4aa</b> )	<b>3aa</b> Yield (%) <sup>c</sup>
1	PPh <sub>3</sub>	toluene	a.t.	24	-	-
2	PPh <sub>3</sub>	Toluene	40	24	> 19/1	27
3	PPh <sub>3</sub>	Toluene	60	24	7.3/1	51
4	PPh <sub>3</sub>	Toluene	80	12	7.3/1	58
5	PPh <sub>3</sub>	Toluene	100	12	5/1	70
6	PPh <sub>3</sub>	Toluene	120	12	2.4/1	38
7	P(4-MeOC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub>	Toluene	a.t.	8	6.5/1	54
8	P(4-MeOC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub>	Toluene	60	6	3.3/1	75
9	P(4-MeOC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub>	Toluene	80	6	3.2/1	75
10	P(4-MeOC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub>	Toluene	100	6	2.9/1	66
11	DPPE	Toluene	a.t.	72	2.1/1	47 <sup>e</sup>
12	DPPE	Toluene	60	12	3.2/1	74 <sup>e</sup>
13	DPPE	Toluene	80	12	3.2/1	67
14	DPPE	Toluene	100	12	1.6/1	59
15	DPPP	Toluene	a.t.	48	1.9/1	65 <sup>e</sup>
16	DPPP	Toluene	60	12	3.1/1	75 <sup>e</sup>
17	DPPP	Toluene	80	12	3.5/1	69
18	DPPP	Toluene	100	12	1.9/1	60
19	PPh <sub>3</sub>	Mesitylene	100	12	2.5/1	52
20	PPh <sub>3</sub>	<i>o</i> -dichlorobenzene	100	12	4.6/1	65
21	PPh <sub>3</sub>	MeCN	100	12	4.6/1	70
22	PPh <sub>3</sub>	1, 4-Dioxane	100	12	6.8/1	41
23	PPh <sub>3</sub>	1, 2-DCE	100	12	2.5/1	42
24	PPh <sub>3</sub>	DMF	100	12	5.1/1	51
25 <sup>d</sup>	PPh <sub>3</sub>	Toluene	100	12	4/1	44
26 <sup>e</sup>	PPh <sub>3</sub>	Toluene	100	12	3.3/1	56

<sup>a</sup> Unless otherwise stated, reactions were carried out with **1a** (0.1 mmol), **2a** (0.15 mmol) and 30 mol% of catalyst in 1.0 mL of solvent. <sup>b</sup> Determined by <sup>1</sup>H NMR analysis of crude product. <sup>c</sup> Isolated yield. <sup>d</sup> 20 mol% of catalyst was used. <sup>e</sup> 40 mol% of catalyst was used.


## D. General procedure for synthesis of *o*-aminophenyl diene **3**



To a dry sealed tube with a magnetic stirring bar was added the corresponding troponimine **1** (0.10 mmol, 1.0 equiv.), MBH-carbonate **2** (0.15 mmol, 1.5 equiv.) and toluene (1.0 mL). Once the solid dissolve completely,  $PPh_3$  (8.0 mg, 30 mol%) was added at room temperature. Then the reaction mixture was stirred at  $100\text{ }^\circ\text{C}$  for 12 – 16 h. When the starting material was consumed monitored by TLC, the reaction solution was purified by column chromatography directly on silica gel with PE/EA as eluent to afford **3**.


## E. Analytic data for the products **3**

### *Ethyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-phenylbut-3-enoate (3aa)*



The title compound was prepared according to the general procedure to afford **3aa** (31.4 mg, 70% yield) as a yellow viscous oil.  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.58 (d,  $J = 8.1$  Hz, 2H), 7.40 (d,  $J = 8.2$  Hz, 1H), 7.21 (d,  $J = 8.1$  Hz, 2H), 7.21 – 7.08 (m, 4H), 6.95 – 6.86 (m, 2H), 6.86 (dd,  $J = 7.4$ , 1.2 Hz, 1H), 6.80 (dd,  $J = 7.8$ , 1.7 Hz, 1H), 6.66 (br, 1H), 6.35 (s, 1H), 6.23 (d,  $J = 1.5$  Hz, 1H), 5.58 (d,  $J = 1.5$  Hz, 1H), 4.11 (q,  $J = 7.1$  Hz, 2H), 2.39 (s, 3H), 1.10 (t,  $J = 7.1$  Hz, 3H).  $^{13}C$  NMR (101 MHz,  $CDCl_3$ )  $\delta$  166.4, 143.7, 143.4, 142.6, 137.3, 136.8, 134.2, 130.6, 129.8, 129.6, 129.0, 128.3, 127.9, 127.2, 127.1, 125.0, 124.9, 122.8, 61.0, 21.5, 13.9. IR (KBr):  $\nu$  3266, 3058, 3027, 2981, 2928, 1718, 1598, 1486, 1402, 1335, 1305, 1164, 1092, 920, 846, 814, 778, 703, 664  $cm^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $C_{26}H_{25}NO_4S$   $[M+H]^+ = 448.1577$ , found = 448.1579.


### *Methyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-phenylbut-3-enoate (3ab)*



The title compound was prepared according to the general procedure to afford **3ab** (29.5 mg, 68% yield) as a yellow viscous oil.  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.58 (d,  $J = 8.3$  Hz, 2H), 7.39 (dd,  $J$


= 8.2, 1.2 Hz, 1H), 7.21 (d,  $J$  = 8.1 Hz, 2H), 7.19 – 7.08 (m, 4H), 6.93 – 6.88 (m, 2H), 6.86 (dd,  $J$  = 7.5, 1.2 Hz, 1H), 6.79 (dd,  $J$  = 7.8, 1.6 Hz, 1H), 6.66 (br, 1H), 6.37 (s, 1H), 6.24 (d,  $J$  = 1.3 Hz, 1H), 5.60 (d,  $J$  = 1.4 Hz, 1H), 3.70 (s, 3H), 2.39 (s, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.9, 143.7, 143.0, 142.4, 137.2, 136.8, 134.2, 130.5, 129.7, 129.6, 129.0, 128.4, 128.3, 127.9, 127.5, 127.2, 125.3, 125.0, 122.7, 52.2, 21.5. IR (KBr):  $\nu$  3295, 2920, 2851, 1723, 1597, 1484, 1332, 1305, 1162, 1091, 917, 813, 779, 703, 663  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{25}\text{H}_{23}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+$  = 434.1421, found = 434.1422.

**Isobutyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-phenylbut-3-enoate(3a  
c)**



The title compound was prepared according to the general procedure to afford **3ac** (31.2 mg, 66% yield) as a yellow viscous oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.58 (d,  $J$  = 8.4 Hz, 2H), 7.40 (dd,  $J$  = 8.2, 1.2 Hz, 1H), 7.21 (d,  $J$  = 8.1 Hz, 2H), 7.19 – 7.09 (m, 4H), 6.94 – 6.90 (m, 2H), 6.88 (td,  $J$  = 7.6, 1.2 Hz, 1H), 6.81 (dd,  $J$  = 7.9, 1.7 Hz, 1H), 6.60 (s, 1H), 6.34 (s, 1H), 6.27 (d,  $J$  = 1.5 Hz, 1H), 5.60 (d,  $J$  = 1.5 Hz, 1H), 3.85 (d,  $J$  = 6.5 Hz, 2H), 2.39 (s, 3H), 1.85 – 1.72 (m, 1H), 0.80 (s, 3H), 0.78 (s, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.4, 143.7, 143.3, 142.7, 137.2, 136.8, 134.2, 130.6, 129.8, 129.6, 129.0, 128.4, 128.3, 128.0, 127.5, 127.2, 125.01, 124.98, 122.7, 71.2, 27.6, 21.5, 19.0. IR (KBr):  $\nu$  3260, 3057, 3026, 2961, 2874, 2832, 1719, 1598, 1487, 1364, 1336, 1164, 1092, 919, 813, 777, 752, 702, 663  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{28}\text{H}_{29}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+$  = 476.1890, found = 476.1895.


**Tert-butyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-phenylbut-3-enoate(3a  
ad)**



The title compound was prepared according to the general procedure to afford **3ad** (37.1 mg, 78% yield) as a yellow viscous oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.61 – 7.55 (m, 2H), 7.42 (dd,  $J$  = 8.2, 1.2 Hz, 1H), 7.21 (d,  $J$  = 8.1 Hz, 2H), 7.21 – 7.09 (m, 4H), 6.95 – 6.90 (m, 2H), 6.87 (td,  $J$  = 7.5, 1.2 Hz, 1H), 6.81 (dd,  $J$  = 7.9, 1.7 Hz, 1H), 6.63 (br, 1H), 6.27 (s, 1H), 6.14 (d,  $J$  = 1.6 Hz, 1H), 5.51 (d,  $J$  = 1.6 Hz, 1H), 2.39 (s, 3H), 1.23 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  165.6,


145.0, 143.7, 143.2, 137.6, 136.7, 134.2, 130.7, 129.8, 129.6, 129.0, 128.29, 128.26, 127.8, 127.1, 126.3, 125.0, 124.0, 122.8, 81.3, 27.6, 21.5. **IR** (KBr):  $\nu$  3249, 3061, 3027, 2979, 2931, 1714, 1599, 1485, 1368, 1335, 1306, 1164, 1092, 920, 850, 812, 753, 701, 664  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{28}\text{H}_{29}\text{NO}_4\text{S} [\text{M}+\text{H}]^+ = 476.1890$ , found = 476.1895.

**Benzyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-phenylbut-3-enoate (3ae)**



The title compound was prepared according to the general procedure to afford **3ae** (27.1 mg, 54% yield) as a yellow viscous oil. **<sup>1</sup>H NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.56 (d,  $J = 8.3$  Hz, 2H), 7.40 (dd,  $J = 8.2, 1.2$  Hz, 1H), 7.33 – 7.27 (m, 3H), 7.23 – 7.06 (m, 8H), 6.91 – 6.83 (m, 3H), 6.78 (dd,  $J = 7.8, 1.8$  Hz, 1H), 6.64 (s, 1H), 6.34 (s, 1H), 6.30 (d,  $J = 1.4$  Hz, 1H), 5.63 (d,  $J = 1.4$  Hz, 1H), 5.10 (s, 2H), 2.36 (s, 3H). **<sup>13</sup>C NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.2, 143.7, 143.0, 142.4, 137.1, 136.7, 135.5, 134.2, 130.6, 129.7, 129.6, 129.0, 128.44, 128.41, 128.38, 128.1, 128.0, 127.9, 127.2, 125.1, 125.0, 122.9, 66.8, 21.5. **IR** (KBr):  $\nu$  3294, 3028, 2920, 2851, 1721, 1581, 1493, 1333, 1194, 1163, 1091, 915, 813, 751, 699, 664  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{28}\text{H}_{29}\text{NO}_4\text{S} [\text{M}+\text{H}]^+ = 510.1734$ , found = 510.1732.

**Ethyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-(o-tolyl)but-3-enoate (3af)**




The title compound was prepared according to the general procedure to afford **3af** (35.1 mg, 76% yield) as a white solid. M.p. 108.2 – 110.7  $^{\circ}\text{C}$ ; **<sup>1</sup>H NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.64 (d,  $J = 8.1$  Hz, 2H), 7.39 (d,  $J = 8.1$  Hz, 1H), 7.23 (d,  $J = 8.1$  Hz, 2H), 7.17 – 6.98 (m, 4H), 6.83 (d,  $J = 7.5$  Hz, 1H), 6.76 (t,  $J = 7.6$  Hz, 1H), 6.64 (br, 1H), 6.59 – 6.56 (m, 2H), 6.07 (s, 1H), 5.32 (s, 1H), 4.22 (q,  $J = 7.1$  Hz, 2H), 2.40 (s, 3H), 1.97 (s, 3H), 1.25 (t,  $J = 7.1$  Hz, 3H). **<sup>13</sup>C NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.8, 143.8, 142.8, 141.1, 136.7, 136.7, 136.1, 134.1, 130.4, 129.8, 129.7, 129.6, 129.5, 128.2, 127.8, 127.2, 125.88, 125.86, 125.8, 125.0, 122.9, 61.1, 21.6, 19.5, 14.0. **IR** (KBr):  $\nu$  3280, 2924, 2854, 1721, 1598, 1484, 1334, 1305, 1191, 1163, 1092, 924, 813, 756, 733, 664  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{27}\text{H}_{27}\text{NO}_4\text{S} [\text{M}+\text{H}]^+ = 462.1734$ , found = 462.1742.




**Ethyl(E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-(m-tolyl)but-3-enoate**

**(3ag)**




The title compound was prepared according to the general procedure to afford **3ag** (31.8 g, 69% yield) as a pale yellow solid. M.p. 73.8 – 76.7 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.57 (d, *J* = 8.0 Hz, 2H), 7.39 (d, *J* = 8.1 Hz, 1H), 7.21 (d, *J* = 8.0 Hz, 2H), 7.12 (t, *J* = 7.7 Hz, 1H), 7.06 – 6.95 (m, 2H), 6.92 – 6.79 (m, 2H), 6.76 (s, 1H), 6.72 – 6.64 (m, 2H), 6.33 (s, 1H), 6.21 (d, *J* = 1.5 Hz, 1H), 5.57 (d, *J* = 1.5 Hz, 1H), 4.12 (q, *J* = 7.1 Hz, 2H), 2.38 (s, 3H), 2.17 (s, 3H), 1.12 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.5, 143.7, 143.5, 142.6, 137.9, 137.2, 136.8, 134.0, 130.5, 129.8, 129.6, 129.4, 128.7, 128.24, 128.17, 127.1, 127.0, 126.2, 125.0, 124.8, 122.8, 61.0, 21.5, 21.2, 13.9. IR (KBr): ν 3280, 2923, 2855, 1721, 1599, 1493, 1484, 1334, 1305, 1163, 1092, 922, 813, 756, 709, 664 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>27</sub>H<sub>27</sub>NO<sub>4</sub>S [M+H]<sup>+</sup> = 462.1734, found = 462.1733.

**Ethyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-(p-tolyl)but-3-enoate**  
**(3ah)**




The title compound was prepared according to the general procedure to afford **3ah** (28.6 g, 62% yield) as a pale yellow solid. M.p. 74.8 – 79.9 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.56 (d, *J* = 8.3 Hz, 2H), 7.40 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.20 (d, *J* = 8.0 Hz, 2H), 7.13 (td, *J* = 7.8, 1.8 Hz, 1H), 6.95 (d, *J* = 7.9 Hz, 2H), 6.90 (td, *J* = 7.5, 1.2 Hz, 1H), 6.85 (dd, *J* = 7.8, 1.7 Hz, 1H), 6.80 (d, *J* = 8.1 Hz, 2H), 6.64 (d, *J* = 3.2 Hz, 1H), 6.29 (s, 1H), 6.21 (d, *J* = 1.5 Hz, 1H), 5.57 (d, *J* = 1.5 Hz, 1H), 4.11 (q, *J* = 7.1 Hz, 2H), 2.39 (s, 3H), 2.27 (s, 3H), 1.12 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.4, 143.7, 143.5, 142.5, 137.8, 136.7, 134.2, 134.0, 130.5, 129.9, 129.6, 129.1, 128.8, 128.2, 127.1, 127.0, 125.0, 124.4, 122.8, 61.0, 21.5, 21.2, 13.9. IR (KBr): ν 3268, 2923, 2853, 1721, 1572, 1485, 1334, 1161, 1092, 916, 847, 814, 757, 663 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>27</sub>H<sub>27</sub>NO<sub>4</sub>S [M+H]<sup>+</sup> = 462.1734, found = 462.1732.

**Ethyl (E)-3-(4-methoxyphenyl)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)but-3-enoate (3ai)**



The title compound was prepared according to the general procedure to afford **3ai** (35.6 g, 74% yield) as a yellow viscous oil. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.59 – 7.52 (m, 2H), 7.40 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.20 (d, *J* = 8.0 Hz, 2H), 7.13 (td, *J* = 8.1, 7.6, 1.9 Hz, 1H), 6.92 (td, *J* = 7.4, 1.2 Hz, 1H), 6.87 (dd, *J* = 7.8, 1.7 Hz, 1H), 6.85 – 6.81 (m, 2H), 6.71 – 6.63 (m, 3H), 6.26 (s, 1H), 6.21 (d, *J* = 1.5 Hz, 1H), 5.58 (d, *J* = 1.6 Hz, 1H), 4.12 (q, *J* = 7.1 Hz, 2H), 3.74 (s, 3H), 2.38 (s, 3H), 1.13 (t, *J* = 7.1 Hz, 3H). **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ 166.5, 159.2, 143.7, 143.6, 142.1, 136.7, 134.0, 130.5, 130.2, 129.9, 129.6, 129.5, 128.2, 127.1, 126.9, 125.0, 124.0, 122.6, 113.8, 61.0, 55.1, 21.5, 13.9. **IR** (KBr): ν 3285, 2929, 2837, 1720, 1605, 1511, 1485, 1334, 1163, 1092, 922, 837, 814, 757, 705, 663 cm<sup>-1</sup>; **HRMS** (ESI): *m/z* calcd for C<sub>27</sub>H<sub>27</sub>NO<sub>5</sub>S [M+H]<sup>+</sup> = 478.1683, found = 478.1680.


**Ethyl (E)-3-(4-fluorophenyl)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)but-3-enoate (3aj)**



The title compound was prepared according to the general procedure to afford **3aj** (22.1 mg, 47% yield) as a colorless oil. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) 7.63 – 7.57 (m, 2H), 7.41 (dd, *J* = 8.1, 1.2 Hz, 1H), 7.22 (d, *J* = 8.0 Hz, 2H), 7.13 (td, *J* = 7.7, 1.6 Hz, 1H), 6.92 – 6.73 (m, 5H), 6.77 (dd, *J* = 8.4, 1.3 Hz, 1H), 6.68 (s, 1H), 6.37 (s, 1H), 6.25 (d, *J* = 1.4 Hz, 1H), 5.61 (d, *J* = 1.4 Hz, 1H), 4.12 (q, *J* = 7.1 Hz, 2H), 2.39 (s, 3H), 1.13 (t, *J* = 7.1 Hz, 3H). **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ 166.2, 162.2 (d, <sup>1</sup>*J*<sub>C-F</sub> = 248.0 Hz), 143.8, 143.3, 141.6, 136.7, 134.3, 133.3 (d, <sup>4</sup>*J*<sub>C-F</sub> = 3.6 Hz), 130.8 (d, <sup>3</sup>*J*<sub>C-F</sub> = 8.0 Hz), 130.5, 129.6, 129.5, 128.5, 127.3, 127.2, 125.1, 125.0, 122.6, 115.3 (d, <sup>2</sup>*J*<sub>C-F</sub> = 21.6 Hz), 61.1, 21.5, 13.9. **<sup>19</sup>F NMR** (376 MHz, CDCl<sub>3</sub>) δ -113.30. **IR** (KBr): ν 3268, 3068, 2982, 2927, 2855, 1720, 1600, 1508, 1486, 1335, 1164, 1092, 918, 842, 815, 758, 706, 662 cm<sup>-1</sup>; **HRMS**


(ESI):  $m/z$  calcd for  $C_{26}H_{24}FNO_4S$   $[M+H]^+$  = 466.1483, found = 466.1485.

***Ethyl (Z)-3-(2-chlorophenyl)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)but-3-enoate (3ak)***



The title compound was prepared according to the general procedure to afford **3ak** (22.1 mg, 46% yield) as a pale yellow solid. M.p. 96.2 – 99.6 °C;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.71 – 7.64 (m, 2H), 7.42 (dd,  $J$  = 8.2, 1.2 Hz, 1H), 7.26 – 7.21 (m, 3H), 7.14 (td,  $J$  = 7.7, 1.8 Hz, 1H), 7.13 – 7.03 (m, 2H), 6.92 (dd,  $J$  = 7.6, 1.8 Hz, 1H), 6.78 (td,  $J$  = 7.7, 1.3 Hz, 1H), 6.75 (s, 1H), 6.66 – 6.60 (m, 2H), 6.17 (d,  $J$  = 1.1 Hz, 1H), 5.40 (d,  $J$  = 1.1 Hz, 1H), 4.22 (q,  $J$  = 7.1 Hz, 2H), 2.40 (s, 3H), 1.25 (t,  $J$  = 7.1 Hz, 3H).  $^{13}C$  NMR (101 MHz,  $CDCl_3$ )  $\delta$  166.2, 143.8, 141.3, 139.4, 136.8, 136.4, 134.4, 133.5, 131.5, 129.7, 129.6, 129.6, 129.5, 129.0, 128.4, 127.8, 127.2, 126.9, 126.6, 124.8, 122.5, 61.1, 21.6, 14.0. IR (KBr):  $\nu$  3287, 2925, 2853, 1721, 1598, 1493, 1334, 1306, 1163, 1092, 923, 814, 754, 663  $cm^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $C_{26}H_{24}ClNO_4S$   $[M+H]^+$  = 482.1188, 484.1158, found = 482.1193, 484.1172.


***Ethyl (E)-3-(3-chlorophenyl)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)but-3-enoate (3al)***



The title compound was prepared according to the general procedure to afford **3al** (22.4 mg, 46% yield) as a pale yellow solid. M.p. 96.2 – 99.3 °C;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.66 – 7.60 (m, 2H), 7.40 (dd,  $J$  = 8.2, 1.3 Hz, 1H), 7.23 (d,  $J$  = 8.0 Hz, 2H), 7.19 – 7.09 (m, 2H), 7.05 (t,  $J$  = 7.9 Hz, 1H), 6.91 (t,  $J$  = 1.9 Hz, 1H), 6.87 (td,  $J$  = 7.6, 1.2 Hz, 1H), 6.80 – 6.70 (m, 3H), 6.42 (s, 1H), 6.27 (d,  $J$  = 1.4 Hz, 1H), 5.62 (d,  $J$  = 1.4 Hz, 1H), 4.14 (q,  $J$  = 7.1 Hz, 2H), 2.39 (s, 3H), 1.14 (t,  $J$  = 7.1 Hz, 3H).  $^{13}C$  NMR (101 MHz,  $CDCl_3$ )  $\delta$  166.1, 143.9, 142.9, 141.2, 139.3, 136.6, 134.4, 134.1, 130.5, 129.7, 129.5, 129.3, 129.0, 128.6, 127.9, 127.7, 127.4, 127.2, 125.9, 125.1, 122.9, 61.1, 21.5, 13.9. IR (KBr):  $\nu$  3301, 2923, 2852, 1721, 1598, 1483, 1333, 1162, 1092, 916, 812,


755, 708, 664  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{ClNO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 482.1188, 484.1188,$   
found = 482.1195, 484.1167.

**Ethyl (E)-3-(4-chlorophenyl)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)but-3-enoate (3am)**



The title compound was prepared according to the general procedure to afford **3am** (25.6 mg, 53% yield) as a white solid. M.p. 69.1 – 70.2  $^{\circ}\text{C}$ ;  **$^1\text{H}$  NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.63 – 7.57 (m, 2H), 7.40 (dd,  $J = 8.2, 1.2$  Hz, 1H), 7.22 (d,  $J = 8.0$  Hz, 2H), 7.13 (dd,  $J = 8.1, 1.7$  Hz, 1H), 7.11 – 7.07 (m, 2H), 6.88 (td,  $J = 7.6, 1.2$  Hz, 1H), 6.85 – 6.80 (m, 2H), 6.77 (dd,  $J = 8.2, 1.3$  Hz, 1H), 6.68 (s, 1H), 6.39 (s, 1H), 6.26 (d,  $J = 1.4$  Hz, 1H), 5.63 (d,  $J = 1.4$  Hz, 1H), 4.13 (q,  $J = 7.1$  Hz, 2H), 2.39 (s, 3H), 1.14 (t,  $J = 7.1$  Hz, 3H).  **$^{13}\text{C}$  NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.2, 143.9, 143.1, 141.5, 136.7, 135.9, 134.4, 133.7, 130.5, 130.4, 129.7, 129.3, 128.6, 128.5, 127.6, 127.2, 125.6, 125.1, 122.5, 61.1, 21.5, 13.9. **IR** (KBr):  $\nu$  3268, 2980, 2925, 1720, 1485, 1334, 1305, 1162, 1091, 916, 836, 813, 754, 663  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{ClNO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 482.1188, 484.1158,$   
found = 482.1195, 484.1167.


**Ethyl (Z)-3-(2,4-dichlorophenyl)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)but-3-enoate (3an)**



The title compound was prepared according to the general procedure to afford **3an** (29.4 mg, 57% yield) as a pale yellow solid. M.p. 87.6 – 91.7  $^{\circ}\text{C}$ ;  **$^1\text{H}$  NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.63 – 7.57 (m, 2H), 7.40 (dd,  $J = 8.2, 1.2$  Hz, 1H), 7.22 (d,  $J = 8.0$  Hz, 2H), 7.13 (dd,  $J = 8.1, 1.7$  Hz, 1H), 7.11 – 7.07 (m, 2H), 6.88 (td,  $J = 7.6, 1.2$  Hz, 1H), 6.85 – 6.80 (m, 2H), 6.77 (dd,  $J = 8.2, 1.3$  Hz, 1H), 6.68 (br, 1H), 6.39 (s, 1H), 6.26 (d,  $J = 1.4$  Hz, 1H), 5.63 (d,  $J = 1.4$  Hz, 1H), 4.13 (q,  $J = 7.1$  Hz, 2H), 2.39 (s, 3H), 1.14 (t,  $J = 7.1$  Hz, 3H).  **$^{13}\text{C}$  NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.2, 143.9, 143.1, 141.5, 136.7, 135.9, 134.4, 133.7, 130.5, 130.4, 129.7, 129.3, 128.6, 128.5, 127.6, 127.2, 125.6,


125.1, 122.5, 61.1, 21.5, 13.9. **IR** (KBr):  $\nu$  3280, 2925, 2853, 1721, 1584, 1334, 1163, 1092, 923, 814, 757, 705, 663  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{23}\text{Cl}_2\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 516.0798$ , 518.0796, found = 516.0801, 518.0782.

**Ethyl (Z)-3-(2-bromophenyl)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)but-3-enoate (3ao)**



The title compound was prepared according to the general procedure to afford **3ao** (25.5 mg, 48% yield) as a pale yellow solid. M.p. 107.3 – 111.6  $^{\circ}\text{C}$ ;  **$^1\text{H}$  NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.72 – 7.65 (m, 2H), 7.48 – 7.40 (m, 2H), 7.24 (d,  $J = 8.0$  Hz, 2H), 7.13 (t,  $J = 7.4$  Hz, 1H), 7.11 – 7.03 (m, 2H), 6.93 (dd,  $J = 7.4, 1.7$  Hz, 1H), 6.78 (t,  $J = 7.6$  Hz, 1H), 6.74 (s, 1H), 6.66 (s, 1H), 6.64 (d,  $J = 7.7$  Hz, 1H), 6.17 (s, 1H), 5.38 (s, 1H), 4.25 (q,  $J = 7.1$  Hz, 2H), 2.40 (s, 3H), 1.28 (t,  $J = 7.2$  Hz, 3H).  **$^{13}\text{C}$  NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.2, 143.8, 141.1, 140.7, 138.4, 136.8, 134.5, 133.0, 131.8, 129.6, 129.5, 129.1, 128.4, 127.6, 127.23, 127.17, 127.0, 124.8, 123.8, 122.5, 61.1, 21.6, 14.1. **IR** (KBr):  $\nu$  3270, 2956, 2924, 2853, 1721, 1598, 1486, 1334, 1162, 1092, 921, 813, 751, 663  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{BrNO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 526.0683$ , 528.0662, found = 526.0700, 528.0672.


**Ethyl (E)-3-(4-bromophenyl)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)but-3-enoate (3ap)**



The title compound was prepared according to the general procedure to afford **3ap** (24.8 mg, 47% yield) as a yellow viscous oil.  **$^1\text{H}$  NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.64 – 7.57 (m, 2H), 7.39 (dd,  $J = 8.2, 1.2$  Hz, 1H), 7.27 – 7.23 (m, 3H), 7.21 (s, 1H), 7.13 (td,  $J = 7.8, 1.6$  Hz, 1H), 6.88 (td,  $J = 7.6, 1.2$  Hz, 1H), 6.80 – 6.73 (m, 4H), 6.41 (s, 1H), 6.26 (d,  $J = 1.4$  Hz, 1H), 5.63 (d,  $J = 1.4$  Hz, 1H), 4.13 (q,  $J = 7.1$  Hz, 2H), 2.39 (s, 3H), 1.14 (t,  $J = 7.1$  Hz, 3H).  **$^{13}\text{C}$  NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.1, 143.9, 143.0, 141.6, 136.7, 136.3, 134.4, 131.5, 130.7, 130.5, 129.7, 129.2, 128.6, 127.7,


127.2, 125.5, 125.1, 122.5, 61.2, 21.6, 13.9. **IR** (KBr):  $\nu$  3270, 2922, 2852, 1721, 1585, 1483, 1332, 1158, 1090, 915, 832, 812, 751, 664  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{BrNO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 526.0683, 528.0662$ , found = 526.0689, 528.0679.

**Ethyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-(3-nitrophenyl)but-3-enoate (3ar)**



The title compound was prepared according to the general procedure to afford **3ar** (22.0 mg, 44% yield) as a yellow viscous oil.  **$^1\text{H}$  NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.03 (ddd,  $J = 8.2, 2.3, 1.1$  Hz, 1H), 7.86 (t,  $J = 2.0$  Hz, 1H), 7.70 – 7.63 (m, 2H), 7.32 (dd,  $J = 8.4, 1.3$  Hz, 1H), 7.28 (d,  $J = 8.0$  Hz, 1H), 7.25 (d,  $J = 8.5$  Hz, 2H), 7.21 (dt,  $J = 7.8, 1.4$  Hz, 1H), 7.13 (td,  $J = 7.8, 1.6$  Hz, 1H), 6.84 (td,  $J = 7.6, 1.2$  Hz, 1H), 6.69 (s, 1H), 6.66 (d,  $J = 7.8$  Hz, 1H), 6.58 (s, 1H), 6.36 (d,  $J = 1.3$  Hz, 1H), 5.74 (d,  $J = 1.3$  Hz, 1H), 4.13 (q,  $J = 7.1$  Hz, 2H), 2.40 (s, 3H), 1.15 (t,  $J = 7.1$  Hz, 3H).  **$^{13}\text{C}$  NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  165.7, 148.1, 144.0, 142.4, 140.3, 139.6, 136.6, 135.4, 134.7, 130.5, 129.8, 129.3, 129.1, 128.9, 128.6, 127.4, 127.2, 125.4, 123.9, 123.3, 122.5, 61.2, 21.5, 13.9. **IR** (KBr):  $\nu$  3250, 3113, 2982, 2925, 2853, 1720, 1598, 1529, 1492, 1348, 1162, 1092, 907, 813, 757, 701, 664  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{N}_2\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+ = 493.1428$ , found = 493.1433.


**Ethyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-(4-nitrophenyl)but-3-enoate (3as)**



The title compound was prepared according to the general procedure to afford **3as** (28.0 mg, 57% yield) as a yellow viscous oil.  **$^1\text{H}$  NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.00 – 7.93 (m, 2H), 7.69 – 7.63 (m, 2H), 7.38 (dd,  $J = 8.2, 1.2$  Hz, 1H), 7.24 (d,  $J = 8.2$  Hz, 2H), 7.15 (td,  $J = 7.8, 1.6$  Hz, 1H), 7.09 – 7.02 (m, 2H), 6.85 (td,  $J = 7.6, 1.2$  Hz, 1H), 6.80 (s, 1H), 6.66 (dd,  $J = 7.9, 1.8$  Hz, 1H), 6.59 (s, 1H), 6.35 (d,  $J = 1.3$  Hz, 1H), 5.74 (d,  $J = 1.3$  Hz, 1H), 4.12 (q,  $J = 7.1$  Hz, 2H), 2.40 (s, 3H), 1.14 (t,  $J = 7.1$  Hz, 3H).  **$^{13}\text{C}$  NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  165.8, 147.0, 144.8, 144.2, 142.5, 140.7,


136.8, 134.8, 130.6, 130.1, 129.8, 129.3, 129.2, 128.6, 127.8, 127.3, 125.4, 123.5, 123.1, 61.4, 21.6, 14.0. **IR** (KBr):  $\nu$  3262, 3112, 2982, 2926, 1720, 1597, 1518, 1343, 1162, 1092, 914, 854, 814, 753, 706, 664  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{N}_2\text{O}_6\text{S} [\text{M}+\text{H}]^+ = 493.1428$ , found = 493.1428.

**Ethyl (Z)-3-(furan-2-yl)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)but-3-enoate (3at)**



The title compound was prepared according to the general procedure to afford **3at** (16.7 mg, 38% yield) as a colorless viscous oil.  **$^1\text{H}$  NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.60 – 7.53 (m, 3H), 7.30 – 7.24 (m, 1H), 7.18 (d,  $J = 1.8$  Hz, 1H), 7.15 (d,  $J = 8.1$  Hz, 2H), 7.13 – 7.00 (m, 2H), 6.88 (s, 1H), 6.38 (d,  $J = 1.4$  Hz, 1H), 6.18 (dd,  $J = 3.5, 1.8$  Hz, 1H), 5.91 (s, 1H), 5.77 (d,  $J = 1.4$  Hz, 1H), 5.69 (d,  $J = 3.5$  Hz, 1H), 4.28 (q,  $J = 7.1$  Hz, 2H), 2.36 (s, 3H), 1.24 (t,  $J = 7.1$  Hz, 3H).  **$^{13}\text{C}$  NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.2, 150.4, 143.6, 142.3, 140.8, 136.5, 134.3, 132.6, 129.5, 129.1, 128.7, 127.6, 127.2, 125.1, 123.4, 122.0, 111.3, 110.8, 61.4, 21.5, 14.1. **IR** (KBr):  $\nu$  3286, 2919, 2850, 1721, 1598, 1493, 1335, 1165, 1092, 916, 813, 741, 664  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{24}\text{H}_{23}\text{NO}_5\text{S} [\text{M}+\text{H}]^+ = 438.1370$  found = 438.1772.


**Ethyl (Z)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-(thiophen-2-yl)but-3-enoate (3au)**



The title compound was prepared according to the general procedure to afford **3au** (26.2 mg, 58% yield) as a pale yellow solid. M.p. 74.9 – 78.5  $^{\circ}\text{C}$ ;  **$^1\text{H}$  NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.56 (d,  $J = 8.2$  Hz, 1H), 7.54 – 7.50 (m, 2H), 7.35 – 7.20 (m, 1H), 7.12 (d,  $J = 8.0$  Hz, 2H), 7.10 – 7.04 (m, 3H), 7.03 (s, 1H), 6.82 (dd,  $J = 5.1, 3.7$  Hz, 1H), 6.71 (dd,  $J = 3.7, 1.2$  Hz, 1H), 6.42 (d,  $J = 1.4$  Hz, 1H), 6.06 (s, 1H), 5.79 (d,  $J = 1.4$  Hz, 1H), 4.29 (q,  $J = 7.1$  Hz, 2H), 2.35 (s, 3H), 1.25 (t,  $J = 7.1$  Hz, 3H).  **$^{13}\text{C}$  NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.3, 143.6, 142.4, 139.2, 136.5, 136.3, 134.8, 129.8, 129.7,


129.5, 129.1, 128.3, 128.2, 127.9, 127.5, 127.1, 126.4, 124.9, 124.1, 121.2, 61.6, 21.5, 14.1. **IR** (KBr):  $\nu$  3269, 3106, 3070, 2981, 2927, 1720, 1598, 1486, 1402, 1335, 1165, 1092, 920, 844, 813, 753, 706, 663  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{24}\text{H}_{23}\text{NO}_5\text{S}$   $[\text{M}+\text{H}]^+ = 454.1141$ , found = 454.1147.

**Ethyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-(naphthalen-1-yl)but-3-enoate (3av)**



The title compound was prepared according to the general procedure to afford **3av** (23.0 mg, 46% yield) as a pale yellow solid. M.p. 113.2 – 117.8  $^{\circ}\text{C}$ ;  **$^1\text{H}$  NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.80 – 7.76 (m, 2H), 7.72 (dd,  $J = 8.2, 1.1$  Hz, 1H), 7.68 – 7.63 (m, 2H), 7.44 – 7.35 (m, 2H), 7.31 – 7.27 (m, 2H), 7.25 (s, 1H), 7.23 (s, 1H), 7.00 – 6.95 (m, 1H), 6.94 (dd,  $J = 7.9, 1.6$  Hz, 1H), 6.88 (s, 1H), 6.78 (d,  $J = 3.1$  Hz, 1H), 6.56 (td,  $J = 7.6, 1.2$  Hz, 1H), 6.46 (dd,  $J = 7.8, 1.6$  Hz, 1H), 6.06 (d,  $J = 1.1$  Hz, 1H), 5.27 (d,  $J = 1.1$  Hz, 1H), 4.24 (q,  $J = 7.1$  Hz, 2H), 2.41 (s, 3H), 1.21 (t,  $J = 7.2$  Hz, 3H).  **$^{13}\text{C}$  NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.9, 143.8, 142.8, 140.1, 136.7, 135.2, 134.1, 133.5, 131.5, 129.9, 129.6, 129.2, 128.3, 128.2, 128.1, 127.74, 127.66, 127.2, 126.3, 125.8, 125.6, 125.3, 124.9, 122.8, 61.2, 21.6, 14.0. **IR** (KBr):  $\nu$  3301, 3040, 2923, 2852, 1720, 1598, 1492, 1333, 1162, 1092, 922, 805, 781, 756, 706, 664  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{30}\text{H}_{27}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 498.1734$ , found = 498.1736.

**Ethyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-(naphthalen-1-yl)but-3-enoate (3aw)**




The title compound was prepared according to the general procedure to afford **3aw** (33.5 mg, 67% yield) as a pale yellow solid. M.p. 112.9 – 116.7  $^{\circ}\text{C}$ ;  **$^1\text{H}$  NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.82 – 7.76 (m, 2H), 7.72 (d,  $J = 8.2$  Hz, 1H), 7.69 – 7.64 (m, 2H), 7.44 – 7.35 (m, 2H), 7.31 – 7.26 (m, 2H), 7.25 (s, 1H), 7.23 (s, 1H), 6.98 (dd,  $J = 7.0, 1.2$  Hz, 1H), 6.94 (td,  $J = 7.7, 1.6$  Hz, 1H), 6.90 (s, 1H), 6.87 (s, 1H), 6.55 (td,  $J = 7.6, 1.2$  Hz, 1H), 6.46 (dd,  $J = 7.9, 1.6$  Hz, 1H), 6.06 (d,  $J = 1.0$  Hz,




1H), 5.27 (d,  $J = 1.0$  Hz, 1H), 4.24 (q,  $J = 7.1$  Hz, 2H), 2.41 (s, 3H), 1.21 (t,  $J = 7.2$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.9, 143.8, 142.8, 140.0, 136.7, 135.2, 134.1, 133.5, 131.5, 130.0, 129.6, 129.4, 129.2, 128.3, 128.2, 128.1, 127.9, 127.8, 127.6, 127.2, 126.30, 126.26, 125.8, 125.6, 125.2, 124.9, 122.9, 61.1, 21.5, 14.0. IR (KBr):  $\nu$  3266, 3044, 2980, 2925, 1719, 1597, 1485, 1334, 1162, 1092, 918, 805, 780, 756, 706, 664  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{30}\text{H}_{27}\text{NO}_4\text{S} [\text{M}+\text{H}]^+ = 498.1734$ , found = 498.1737.

**Ethyl (E)-2-methylene-4-(2-((4-methylphenyl)sulfonamido)phenyl)-3-(quinolin-3-yl)but-3-enoate (3ax)**



The title compound was prepared according to the general procedure to afford **3ax** (26.2 mg, 53% yield) as a green viscous oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.34 (d,  $J = 2.2$  Hz, 1H), 7.99 (d,  $J = 8.4$  Hz, 1H), 7.75 (d,  $J = 2.2$  Hz, 1H), 7.71 – 7.60 (m, 4H), 7.50 (t,  $J = 7.5$  Hz, 1H), 7.35 (d,  $J = 8.1$  Hz, 1H), 7.21 (d,  $J = 8.0$  Hz, 2H), 7.11 (t,  $J = 7.8$  Hz, 1H), 6.85 (s, 1H), 6.80 (t,  $J = 7.5$  Hz, 1H), 6.73 (dd,  $J = 7.8, 1.6$  Hz, 1H), 6.61 (s, 1H), 6.38 (d,  $J = 1.3$  Hz, 1H), 5.77 (d,  $J = 1.4$  Hz, 1H), 4.10 (q,  $J = 7.1$  Hz, 2H), 2.37 (s, 3H), 1.06 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.0, 151.2, 146.9, 144.0, 142.9, 139.2, 136.6, 135.4, 134.7, 131.0, 130.5, 129.7, 129.7, 129.4, 129.2, 129.0, 128.3, 127.9, 127.4, 127.2, 127.0, 126.9, 125.5, 123.1, 61.2, 21.6, 13.9. IR (KBr):  $\nu$  3267, 3038, 2980, 2925, 2853, 1720, 1598, 1493, 1333, 1161, 1092, 917, 814, 788, 755, 662  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{29}\text{H}_{26}\text{N}_2\text{O}_4\text{S} [\text{M}+\text{H}]^+ = 499.1686$ , found = 499.1689.


**Ethyl (E)-2-methylene-4-(2-(methylsulfonamido)phenyl)-3-phenylbut-3-enoate (3ba)**



The title compound was prepared according to the general procedure to afford **3ba** (23.6 mg, 64% yield) as a yellow viscous oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.43 (dd,  $J = 8.2, 1.2$  Hz, 1H), 7.24 – 7.17 (m, 4H), 7.13 – 7.06 (m, 2H), 7.06 (d,  $J = 1.7$  Hz, 1H), 7.01 (td,  $J = 7.5, 1.2$  Hz, 1H), 6.80


(s, 1H), 6.54 (s, 1H), 6.34 (d,  $J = 1.3$  Hz, 1H), 5.80 (d,  $J = 1.3$  Hz, 1H), 4.16 (q,  $J = 7.1$  Hz, 2H), 2.75 (s, 3H), 1.15 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.5, 143.1, 142.6, 137.5, 134.0, 130.8, 129.1, 128.7, 128.6, 128.5, 128.1, 127.9, 125.4, 124.8, 120.7, 61.2, 39.2, 13.9. IR (KBr):  $\nu$  3278, 3024, 2979, 2929, 2852, 1720, 1599, 1485, 1326, 1154, 1097, 970, 918, 761, 702  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{20}\text{H}_{21}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 372.1264$ , found = 372.1271.

**Ethyl (E)-2-methylene-4-(2-((4-nitrophenyl)sulfonamido)phenyl)-3-phenylbut-3-enoate (3ca)**




The title compound was prepared according to the general procedure to afford **3ca** (28.8 mg, 60% yield) as a yellow solid. M.p. 125.5 – 129.9 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.28 – 8.21 (m, 2H), 7.91 – 7.84 (m, 2H), 7.36 (dd,  $J = 8.2, 1.2$  Hz, 1H), 7.25 – 7.04 (m, 4H), 6.97 (dd,  $J = 7.7, 1.2$  Hz, 1H), 6.95 – 6.89 (m, 3H), 6.87 (dt,  $J = 7.8, 1.1$  Hz, 1H), 6.41 (s, 1H), 6.24 (d,  $J = 1.2$  Hz, 1H), 5.57 (d,  $J = 1.2$  Hz, 1H), 4.16 (q,  $J = 7.1$  Hz, 2H), 1.18 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.4, 150.1, 145.3, 142.9, 142.4, 137.1, 132.9, 130.8, 130.4, 129.0, 128.5, 128.4, 128.2, 127.5, 125.9, 125.0, 124.2, 123.4, 61.2, 13.9. IR (KBr):  $\nu$  3286, 3027, 2980, 2926, 2853, 1720, 1605, 1530, 1484, 1349, 1310, 1168, 1091, 925, 855, 778, 736, 702, 684  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{20}\text{H}_{21}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 479.1271$ , found = 479.1272.

**Ethyl (E)-4-(2-((4-methoxyphenyl)sulfonamido)phenyl)-2-methylene-3-phenylbut-3-enoate (3da)**



The title compound was prepared according to the general procedure to afford **3da** (32.0 mg, 71% yield) as a pale yellow solid. M.p. 96.6 – 101.1 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.67 – 7.60 (m, 2H), 7.40 (d,  $J = 8.2$  Hz, 1H), 7.20 – 7.08 (m, 4H), 6.94 – 6.82 (m, 5H), 6.80 (d,  $J = 7.8$  Hz, 1H), 6.67 – 6.60 (m, 1H), 6.38 (d,  $J = 1.9$  Hz, 1H), 6.24 (d,  $J = 1.7$  Hz, 1H), 5.62 (d,  $J = 1.6$  Hz, 1H), 4.11 (qd,  $J = 7.1, 1.6$  Hz, 2H), 3.82 (d,  $J = 1.7$  Hz, 3H), 1.10 (td,  $J = 7.2, 1.6$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.4, 163.0, 143.4, 142.6, 137.3, 134.2, 131.2, 130.6, 129.7, 129.3, 129.0, 128.3, 127.8, 127.2, 124.95, 124.88, 122.7, 114.1, 61.0, 55.5, 13.9. IR (KBr):  $\nu$  3280, 2927, 2851, 1721, 1596, 1494, 1333, 1302, 1156, 1093, 916, 833, 752, 701  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{25}\text{H}_{22}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 464.1526$ , found = 464.1534.


## F. General procedure for synthesis of 4



To a dry sealed tube with a magnetic stirring bar was added the corresponding troponimines **1** (0.1 mmol, 1.0 equiv.), MBH-carbonates **2** (0.1 mmol, 1.0 equiv.) and toluene (1.0 mL). Once the solid dissolve completely, the catalyst PCy<sub>3</sub> (8.4 mg, 30 mol%) was added at room temperature. Then the reaction mixture was stirred at 80 °C for 3 – 6 h and monitored by TLC. The reaction solution was purified by column chromatography directly on silica gel with PE/EA as eluent to afford **4**.


## G. Analytic data for 4

### *Ethyl 4-phenyl-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4aa)*



The title compound was prepared according to the general procedure to afford **4aa** (41.6 mg, 93% yield) as a white solid. M.p. 110.2 – 112.1 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66 – 7.57 (m, 1H), 7.56 – 7.50 (m, 2H), 7.31 – 7.18 (m, 6H), 7.13 (d, *J* = 8.0 Hz, 2H), 7.10 – 7.05 (m, 2H), 6.33 (d, *J* = 1.4 Hz, 1H), 4.60 (dd, *J* = 14.4, 5.6 Hz, 1H), 4.16 (ddd, *J* = 9.7, 5.6, 1.5 Hz, 1H), 3.94 (dd, *J* = 14.4, 9.7 Hz, 1H), 3.84 (q, *J* = 7.1 Hz, 2H), 2.31 (s, 3H), 0.89 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.4, 143.4, 142.1, 139.8, 138.6, 137.9, 133.3, 132.2, 129.8, 129.4, 128.9, 128.1, 127.9, 127.6, 127.5, 127.1, 126.5, 61.0, 52.1, 49.6, 21.4, 13.7. IR (KBr): ν 3027, 2925, 1728, 1630, 1597, 1349, 1304, 1162, 1093, 1030, 813, 767, 696 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>26</sub>H<sub>25</sub>NO<sub>4</sub>S [M+H]<sup>+</sup> = 448.1577, found = 448.1582.


### *Methyl 4-phenyl-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ab)*



The title compound was prepared according to the general procedure to afford **4ab** (36.7 mg, 85% yield) as a white solid. M.p. 110.1 – 112.2 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66 – 7.57 (m, 1H), 7.57 – 7.50 (m, 2H), 7.31 – 7.24 (m, 5H), 7.23 – 7.18 (m, 1H), 7.14 (d, *J* = 8.0 Hz, 2H), 7.10 – 7.04 (m, 2H), 6.35 (d, *J* = 1.3 Hz, 1H), 4.58 (dd, *J* = 14.4, 5.5 Hz, 1H), 4.17 (ddd, *J* = 9.4, 5.5, 1.4


Hz, 1H), 3.97 (dd,  $J = 14.4, 9.4$  Hz, 1H), 3.39 (s, 3H), 2.32 (s, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  170.9, 143.5, 142.1, 139.6, 138.6, 137.9, 133.2, 132.2, 130.0, 129.5, 128.8, 128.2, 128.0, 127.6, 127.5, 127.1, 126.4, 52.2, 52.1, 49.6, 21.4. IR (KBr):  $\nu$  3027, 2953, 2926, 1737, 1630, 1597, 1401, 1349, 1161, 1093, 814, 765, 696, 662  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{25}\text{H}_{23}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 434.1421$ , found = 434.1421.

**Isobutyl 4-phenyl-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ac)**




The title compound was prepared according to the general procedure to afford **4ac** (35.3 mg, 74% yield) as a white solid. M.p. 83.8 – 87.6  $^{\circ}\text{C}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.65 – 7.58 (m, 1H), 7.56 – 7.50 (m, 2H), 7.31 – 7.18 (m, 6H), 7.13 (d,  $J = 8.1$  Hz, 2H), 7.09 (dt,  $J = 7.7, 1.4$  Hz, 2H), 6.34 (d,  $J = 1.4$  Hz, 1H), 4.61 (dd,  $J = 14.4, 5.6$  Hz, 1H), 4.17 (ddd,  $J = 9.7, 5.6, 1.4$  Hz, 1H), 3.96 (dd,  $J = 14.4, 9.7$  Hz, 1H), 3.56 (d,  $J = 6.6$  Hz, 2H), 2.31 (s, 3H), 1.67 – 1.57 (m, 1H), 0.72 (d,  $J = 2.1$  Hz, 3H), 0.70 (d,  $J = 2.1$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  170.5, 143.4, 142.1, 139.7, 138.5, 137.8, 133.3, 132.1, 129.8, 129.4, 128.9, 128.2, 127.9, 127.5, 127.1, 126.4, 71.2, 52.3, 49.6, 27.4, 21.4, 18.9, 18.8. IR (KBr):  $\nu$  3028, 2958, 2873, 1728, 1630, 1351, 1291, 1217, 1162, 1093, 813, 766, 696  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{28}\text{H}_{29}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 476.1890$ , found = 476.1894.

**Tert-butyl 4-phenyl-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ad)**



The title compound was prepared according to the general procedure to afford **4ad** (34.6 mg, 73% yield) as a white solid. M.p. 99.6 – 105.6  $^{\circ}\text{C}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.65 – 7.58 (m, 1H), 7.56 – 7.48 (m, 2H), 7.36 – 7.17 (m, 6H), 7.15 – 7.05 (m, 4H), 6.29 (d,  $J = 1.4$  Hz, 1H), 4.62 (dd,  $J = 14.4, 5.6$  Hz, 1H), 4.05 (ddd,  $J = 9.9, 5.6, 1.5$  Hz, 1H), 3.87 (dd,  $J = 13.0, 8.6$  Hz, 1H), 2.29 (s, 3H), 1.06 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  169.4, 143.3, 142.3, 140.4, 138.5, 137.9, 133.5, 132.1, 129.41, 129.38, 129.2, 128.0, 127.8, 127.5, 127.4, 127.0, 126.7, 81.4, 52.2, 50.4, 27.3, 21.4. IR (KBr):  $\nu$  3027, 2977, 2929, 1726, 1351, 1304, 1162, 1094, 809, 764, 697  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{28}\text{H}_{29}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 476.1890$ , found = 476.1896.


**Benzyl 4-phenyl-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ae)**



The title compound was prepared according to the general procedure to afford **4ae** (35.6 mg, 70%


yield) as a yellow viscous oil.  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.65 – 7.56 (m, 1H), 7.55 – 7.49 (m, 2H), 7.31 – 7.18 (m, 8H), 7.21 – 7.13 (m, 1H), 7.11 (d,  $J = 8.1$  Hz, 2H), 7.08 – 7.02 (m, 2H), 7.01 – 6.96 (m, 2H), 6.34 (d,  $J = 1.4$  Hz, 1H), 4.81 (s, 2H), 4.59 (dd,  $J = 14.5, 5.6$  Hz, 1H), 4.23 (ddd,  $J = 9.5, 5.6, 1.5$  Hz, 1H), 3.98 (dd,  $J = 14.5, 9.5$  Hz, 1H), 2.30 (s, 3H).  $^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  170.3, 143.4, 142.0, 139.5, 138.6, 137.8, 135.1, 133.1, 132.2, 130.0, 129.4, 128.7, 128.4, 128.21, 128.18, 128.1, 127.9, 127.6, 127.5, 127.1, 126.5, 66.9, 52.1, 49.7, 21.4. **IR** (KBr):  $\nu$  2923, 1727, 1630, 1586, 1349, 1162, 1093, 813, 766, 696  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{31}\text{H}_{27}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 510.1734$ , found = 510.1731.

**Ethyl 4-(*o*-tolyl)-1-tosyl-2,3-dihydro-1H-benzo[*b*]azepine-3-carboxylate (4af)**




The title compound was prepared according to the general procedure to afford **4af** (37.64 mg, 81% yield) as a white solid. M.p. 104.5 – 103.7 °C;  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.64 – 7.58 (m, 3H), 7.28 – 7.16 (m, 5H), 7.15 – 7.11 (m, 2H), 7.07 (dp,  $J = 8.6, 4.0$  Hz, 1H), 6.73 (d,  $J = 7.5$  Hz, 1H), 6.23 (d,  $J = 2.2$  Hz, 1H), 4.56 (dd,  $J = 14.7, 5.1$  Hz, 1H), 4.11 (ddd,  $J = 11.0, 5.1, 2.2$  Hz, 1H), 3.85 – 3.70 (m, 3H), 2.38 (s, 3H), 2.21 (s, 3H), 0.83 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  170.0, 143.6, 141.7, 139.0, 138.3, 135.2, 132.6, 132.2, 131.1, 130.3, 129.7, 128.5, 127.84, 127.77, 127.3, 127.2, 127.1, 125.2, 60.8, 51.3, 50.5, 21.5, 19.7, 13.5. **IR** (KBr):  $\nu$  2925, 2854, 1731, 1630, 1492, 1351, 1304, 1162, 1093, 763  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{27}\text{H}_{27}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 462.1734$ , found = 462.1737.

**Ethyl 4-(*m*-tolyl)-1-tosyl-2,3-dihydro-1H-benzo[*b*]azepine-3-carboxylate (4ag)**




The title compound was prepared according to the general procedure to afford **4ag** (42.0 mg, 91% yield) as a white solid. M.p. 113.2 – 117.4 °C;  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.65 – 7.58 (m, 1H), 7.53 (d,  $J = 8.1$  Hz, 2H), 7.29 – 7.23 (m, 2H), 7.22 – 7.13 (m, 4H), 7.05 (d,  $J = 7.5$  Hz, 1H), 6.87 – 6.86 (m, 2H), 4.59 (dd,  $J = 14.4, 5.5$  Hz, 1H), 4.12 (ddd,  $J = 9.6, 5.5, 1.4$  Hz, 1H), 3.94 (dd,  $J = 14.4, 9.5$  Hz, 1H), 3.85 (qd,  $J = 7.1, 2.8$  Hz, 2H), 2.33 (s, 3H), 2.32 (s, 3H), 0.90 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  170.4, 143.3, 142.1, 139.9, 138.5, 137.9, 137.6, 133.4, 132.1, 129.5, 129.4, 129.0, 128.2, 127.9, 127.8, 127.5, 127.2, 127.1, 123.6, 60.9, 52.2, 49.6, 21.4, 21.4, 13.7. **IR** (KBr):  $\nu$  2850, 1726, 1630, 1586, 1346, 1302, 1162, 1093, 815, 710, 664  $\text{cm}^{-1}$ ; **HRMS**(ESI):  $m/z$  calcd for  $\text{C}_{27}\text{H}_{27}\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 462.1734$ , found = 462.1737.

**Ethyl 4-(p-tolyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ah)**




The title compound was prepared according to the general procedure to afford **4ah** (39.2 mg, 85% yield) as a pale yellow solid. M.p. 111.4 – 114.8 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.65 – 7.58 (m, 1H), 7.52 (d, *J* = 7.9 Hz, 2H), 7.28 – 7.23 (m, 2H), 7.22 – 7.16 (m, 1H), 7.13 (d, *J* = 8.0 Hz, 2H), 7.07 (d, *J* = 7.8 Hz, 2H), 6.97 (d, *J* = 7.8 Hz, 2H), 6.31 (s, 1H), 4.59 (dd, *J* = 14.4, 5.5 Hz, 1H), 4.17 – 4.09 (m, 2H), 3.93 (dd, *J* = 14.4, 9.6 Hz, 1H), 3.85 (q, *J* = 7.1 Hz, 2H), 2.32 (s, 3H), 2.31 (s, 3H), 0.92 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.5, 143.4, 139.7, 139.3, 138.5, 137.9, 137.3, 133.4, 132.1, 129.4, 129.2, 128.9, 128.8, 127.8, 127.5, 127.1, 126.4, 61.0, 52.2, 49.6, 21.4, 21.0, 13.7. IR (KBr): ν 2980, 2924, 1728, 1630, 1597, 1401, 1350, 1304, 1161, 1093, 813, 708 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>27</sub>H<sub>27</sub>NO<sub>4</sub>S [M+H]<sup>+</sup> = 462.1734, found = 462.1740.

**Ethyl 4-(4-methoxyphenyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ai)**




The title compound was prepared according to the general procedure to afford **4ai** (26.2 mg, 55% yield) as a white solid. M.p. 95.2 – 96.6 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.64 – 7.56 (m, 1H), 7.52 (d, *J* = 8.0 Hz, 2H), 7.28 – 7.23 (m, 2H), 7.22 – 7.16 (m, 1H), 7.13 (d, *J* = 8.1 Hz, 2H), 7.04 – 6.99 (m, 2H), 6.83 – 6.76 (m, 2H), 6.28 (s, 1H), 4.58 (dd, *J* = 14.4, 5.5 Hz, 1H), 4.12 (ddd, *J* = 9.8, 5.5, 1.3 Hz, 2H), 3.89 (dd, *J* = 14.4, 5.5 Hz, 1H), 3.86 (q, *J* = 7.1 Hz, 2H), 3.80 (s, 3H), 2.32 (s, 3H), 0.93 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.5, 159.1, 143.4, 139.3, 138.4, 137.9, 134.6, 133.4, 132.1, 129.4, 128.9, 128.8, 127.7, 127.6, 127.5, 127.1, 113.4, 61.0, 55.3, 52.0, 49.7, 21.4, 13.8. IR (KBr): ν 2979, 2934, 2837, 1732, 1631, 1606, 1512, 1350, 1162, 1094, 1032, 910, 815, 709, 655 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>27</sub>H<sub>27</sub>NO<sub>5</sub>S [M+H]<sup>+</sup> = 478.1683, found = 468.1684.

**Ethyl 4-(4-fluorophenyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4aj)**




The title compound was prepared according to the general procedure to afford **4aj** (38.4 mg, 83 % yield) as a white solid. M.p. 81.2 – 84.3 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.64 – 7.56 (m, 1H), 7.56 – 7.50 (m, 2H), 7.30 – 7.24 (m, 2H), 7.23 – 7.17 (m, 1H), 7.15 (d, *J* = 8.0 Hz, 2H), 7.08 – 7.03 (m, 2H), 7.02 – 6.90 (m, 2H), 6.30 (d, *J* = 1.5 Hz, 1H), 4.58 (dd, *J* = 14.5, 5.6 Hz, 1H), 4.13 (ddd, *J* = 9.9, 5.6, 1.5 Hz, 1H), 3.94 – 3.89 (m, 1H), 3.86 (q, *J* = 7.1 Hz, 2H), 2.32 (s, 3H), 0.92 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.2, 162.2 (d, <sup>1</sup>*J*<sub>C-F</sub> = 247.1 Hz), 143.5, 138.7, 138.2 (d, <sup>4</sup>*J*<sub>C-F</sub> = 3.3 Hz), 137.9, 133.0, 132.2, 130.0, 129.4, 128.8, 128.2 (d, <sup>3</sup>*J*<sub>C-F</sub> = 8.0 Hz), 128.0, 127.6, 127.1, 114.9 (d, <sup>2</sup>*J*<sub>C-F</sub> = 21.4 Hz), 61.1, 51.9, 49.9, 21.4, 13.7. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ -114.44. IR (KBr): ν 2981, 2930, 1732, 1630, 1600, 1509, 1352, 1304, 1163, 1095, 835, 814, 758, 709, 655 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>26</sub>H<sub>24</sub>NO<sub>4</sub>S [M+H]<sup>+</sup> = 466.1483, found = 466.1487.

**Ethyl 4-(2-chlorophenyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ak)**



The title compound was prepared according to the general procedure to afford **4ak** (42.0 mg, 87 % yield) as a pale yellow solid. M.p. 115.4 – 117.3 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72 – 7.60 (m, 3H), 7.36 – 7.30 (m, 1H), 7.26 – 7.15 (m, 7H), 7.05 – 6.95 (m, 1H), 6.36 (d, *J* = 2.1 Hz, 1H), 4.59 (dd, *J* = 14.7, 5.1 Hz, 1H), 4.30 (ddd, *J* = 10.3, 5.1, 2.1 Hz, 1H), 3.89 (dd, *J* = 14.7, 10.3 Hz, 1H), 3.85 – 3.79 (m, 2H), 2.36 (s, 3H), 0.89 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.8, 143.6, 141.0, 139.2, 137.7, 137.3, 132.9, 132.6, 132.5, 131.5, 130.8, 129.6, 129.5, 128.7, 128.2, 127.3, 127.2, 127.0, 126.4, 61.0, 50.5, 50.3, 21.5, 13.6. IR (KBr): ν 2980, 2926, 1729, 1630, 1597, 1350, 1305, 1161, 1093, 813, 758, 688, 655 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>26</sub>H<sub>24</sub>ClNO<sub>4</sub>S [M+H]<sup>+</sup> = 482.1188, 484.1158, found = 482.1193, 484.1172.


**Ethyl 4-(3-chlorophenyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4al)**



The title compound was prepared according to the general procedure to afford **4al** (45.2 mg, 94 % yield) as a white solid. M.p. 97.4 – 99.5 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.65 – 7.61 (m, 1H), 7.54 (d, *J* = 2.5 Hz, 1H), 7.52 (d, *J* = 2.4 Hz, 1H), 7.33 – 7.27 (m, 2H), 7.25 – 7.15 (m, 5H), 7.01


– 6.96 (m, 1H), 6.94 (d,  $J = 2.3$  Hz, 1H), 6.31 (s, 1H), 4.60 (ddd,  $J = 14.4, 5.5, 2.4$  Hz, 1H), 4.07 (dd,  $J = 9.4, 6.2$  Hz, 1H), 3.95 (dd,  $J = 9.8, 2.4$  Hz, 1H), 3.91 – 3.82 (m, 2H), 2.35 (s, 3H), 0.94 (td,  $J = 7.1, 2.4$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  170.1, 143.9, 143.6, 138.7, 138.4, 138.0, 133.9, 132.9, 132.3, 130.7, 129.5, 129.4, 129.2, 128.3, 127.7, 127.5, 127.1, 126.8, 124.7, 61.2, 52.1, 49.4, 21.5, 13.7. IR (KBr):  $\nu$  2925, 1730, 1630, 1592, 1351, 1305, 1162, 1094, 813, 785, 691, 657  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{ClNO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 482.1188, 484.1158$ , found = 482.1195, 484.1167.

**Ethyl 4-(4-chlorophenyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4am)**



The title compound was prepared according to the general procedure to afford **4am** (43.4 mg, 90 % yield) as a white solid. M.p. 93.6 – 95.8 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.62 – 7.58 (m, 1H), 7.53 (d,  $J = 8.2$  Hz, 2H), 7.30 – 7.27 (m, 2H), 7.26 – 7.18 (m, 3H), 7.14 (d,  $J = 8.1$  Hz, 2H), 7.05 – 6.99 (m, 2H), 6.32 (d,  $J = 1.4$  Hz, 1H), 4.58 (dd,  $J = 14.5, 5.6$  Hz, 1H), 4.13 (ddd,  $J = 9.8, 5.7, 1.5$  Hz, 1H), 3.94 – 3.81 (m, 3H), 2.32 (s, 3H), 0.94 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  170.2, 143.5, 140.7, 138.7, 138.5, 137.9, 133.4, 132.9, 132.3, 130.3, 129.5, 128.8, 128.3, 128.2, 127.9, 127.6, 127.1, 61.2, 51.9, 49.7, 21.4, 13.8. IR (KBr):  $\nu$  2982, 2930, 1732, 1632, 1597, 1492, 1401, 1351, 1305, 1162, 1094, 815, 758, 689, 654  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{ClNO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 482.1188, 484.1158$ , found = 482.1194, 484.1175.


**Ethyl 4-(2,4-dichlorophenyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4an)**



The title compound was prepared according to the general procedure to afford **4an** (41.3 mg, 80% yield) as a yellow viscous oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.67 – 7.59 (m, 3H), 7.36 (t,  $J = 1.7$  Hz, 1H), 7.26 – 7.14 (m, 6H), 6.94 (dd,  $J = 8.2, 1.3$  Hz, 1H), 6.34 (s, 1H), 4.56 (dd,  $J = 14.8, 5.1$  Hz, 1H), 4.25 (ddd,  $J = 10.1, 5.0, 1.8$  Hz, 1H), 3.93 – 3.82 (m, 3H), 2.37 (s, 3H), 0.96 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  169.7, 143.6, 139.6, 139.3, 137.7, 136.2, 133.8, 133.4, 133.0, 131.6, 131.3, 129.6, 129.3, 128.4, 127.3, 127.2, 127.1, 126.7, 61.1, 50.5, 50.4, 21.5, 13.7. IR (KBr):  $\nu$  3063, 2980, 2958, 2926, 1732, 1597, 1493, 1351, 1306, 1162, 1099, 815, 764, 708, 691, 654  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{23}\text{Cl}_2\text{NO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 516.0798, 518.0769$ , found = 516.0794, 518.0784.




**Ethyl 4-(2-bromophenyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ao)**




The title compound was prepared according to the general procedure to afford **4ao** (36.3 mg, 69% yield) as a white solid. M.p. 127.5 – 132.6 °C;  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.69 – 7.65 (m, 2H), 7.64 – 7.59 (m, 1H), 7.54 (dd,  $J = 8.0, 1.3$  Hz, 1H), 7.28 – 7.19 (m, 6H), 7.11 (td,  $J = 7.7, 1.8$  Hz, 1H), 6.97 (dd,  $J = 7.6, 1.7$  Hz, 1H), 6.36 (d,  $J = 2.1$  Hz, 1H), 4.55 (dd,  $J = 14.7, 5.1$  Hz, 1H), 4.31 (ddd,  $J = 10.3, 5.0, 2.1$  Hz, 1H), 3.92 (dd,  $J = 15.4, 9.6$  Hz, 1H), 3.84 (qd,  $J = 7.1, 2.3$  Hz, 2H), 2.37 (s, 3H), 0.91 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  169.8, 143.6, 142.8, 139.4, 138.5, 137.8, 133.0, 132.8, 132.7, 131.4, 130.7, 129.6, 128.8, 128.2, 127.4, 127.0, 126.9, 122.6, 61.0, 50.8, 50.3, 21.5, 13.6. **IR** (KBr):  $\nu$  2979, 2926, 2854, 1731, 1630, 1597, 1493, 1350, 1305, 1161, 1094, 814, 760, 709, 680, 654  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{BrNO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 526.0683, 528.0662$ , found = 526.0683, 528.0673.

**Ethyl 4-(4-bromophenyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ap)**



The title compound was prepared according to the general procedure to afford **4ap** (36.5 mg, 70% yield) as a white solid. M.p. 107.1 – 110.3 °C;  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.64 (dd,  $J = 5.8, 3.5$  Hz, 1H), 7.61 – 7.52 (m, 2H), 7.47 – 7.40 (m, 2H), 7.34 – 7.29 (m, 2H), 7.24 (dd,  $J = 5.8, 3.5$  Hz, 1H), 7.18 (d,  $J = 8.1$  Hz, 2H), 7.03 – 6.96 (m, 2H), 6.36 (d,  $J = 1.4$  Hz, 1H), 4.62 (dd,  $J = 14.5, 5.6$  Hz, 1H), 4.17 (ddd,  $J = 9.9, 5.6, 1.5$  Hz, 1H), 3.99 – 3.86 (m, 3H), 2.36 (s, 3H), 0.98 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  169.8, 143.6, 142.8, 139.4, 138.5, 137.8, 133.0, 132.8, 132.7, 131.4, 130.7, 129.6, 128.8, 128.2, 127.4, 127.0, 126.9, 122.6, 61.0, 50.8, 50.3, 21.5, 13.6. **IR** (KBr):  $\nu$  2921, 2852, 1727, 1631, 1597, 1493, 1485, 1348, 1304, 1161, 1093, 814, 757, 709, 654  $\text{cm}^{-1}$ ; **HRMS** (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{BrNO}_4\text{S}$   $[\text{M}+\text{H}]^+ = 526.0683, 528.0662$ , found = 526.0699, 528.0670.


**Ethyl 4-(3-nitrophenyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ar)**



The title compound was prepared according to the general procedure to afford **4ar** (47.4 mg, 96% yield) as a pale yellow solid. M.p. 116.2 – 118.7 °C;  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.14 – 8.08


(m, 1H), 7.87 – 7.86 (m, 1H), 7.68 – 7.61 (m, 1H), 7.58 – 7.52 (m, 2H), 7.50 – 7.44 (m, 2H), 7.36 – 7.29 (m, 2H), 7.28 – 7.23 (m, 1H), 7.21 (d,  $J = 8.0$  Hz, 2H), 6.40 (d,  $J = 1.5$  Hz, 1H), 4.64 (dd,  $J = 14.6, 5.6$  Hz, 1H), 4.19 (ddd,  $J = 9.9, 5.7, 1.5$  Hz, 1H), 3.98 – 3.83 (m, 3H), 2.31 (s, 3H), 0.93 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  169.8, 148.0, 143.9, 143.9, 138.9, 137.9, 137.3, 132.6, 132.6, 132.3, 131.9, 129.6, 129.2, 129.0, 128.7, 127.7, 127.0, 122.3, 121.5, 61.3, 51.8, 49.5, 21.4, 13.8. IR (KBr):  $\nu$  2916, 2850, 1727, 1630, 1581, 1530, 1493, 1347, 1161, 1092, 812, 711, 656  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{N}_2\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+ = 493.1428$ , found = 493.1425.

**Ethyl 4-(4-nitrophenyl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4as)**




The title compound was prepared according to the general procedure to afford **4as** (47.6 mg, 97% yield) as a yellow solid. M.p. 148.2 – 149.6  $^{\circ}\text{C}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.14 (d,  $J = 8.7$  Hz, 2H), 7.62 – 7.57 (m, 1H), 7.55 (d,  $J = 8.0$  Hz, 2H), 7.33 – 7.27 (m, 3H), 7.25 – 7.24 (m, 2H), 7.16 (d,  $J = 8.0$  Hz, 2H), 6.46 (s, 1H), 4.60 (dd,  $J = 14.6, 5.6$  Hz, 1H), 4.23 (dd,  $J = 9.5, 6.0$  Hz, 1H), 3.97 – 3.83 (m, 3H), 2.32 (s, 3H), 0.94 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  169.8, 148.9, 146.9, 143.7, 139.0, 137.9, 137.6, 132.7, 132.4, 132.2, 129.5, 128.8, 128.6, 127.7, 127.3, 127.1, 123.5, 61.4, 51.9, 49.6, 21.4, 13.8. IR (KBr):  $\nu$  2925, 2853, 1728, 1630, 1593, 1514, 1345, 1162, 1094, 852, 814, 760, 710, 654  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{24}\text{N}_2\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+ = 493.1428$ , found = 493.1430.

**Ethyl 4-(furan-2-yl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4at)**




The title compound was prepared according to the general procedure to afford **4at** (43.3 mg, 98% yield) as a yellow solid. M.p. 73.4 – 76.8  $^{\circ}\text{C}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.59 – 7.52 (m, 1H), 7.45 – 7.38 (m, 2H), 7.31 (d,  $J = 1.8$  Hz, 1H), 7.26 – 7.20 (m, 3H), 6.98 (d,  $J = 8.0$  Hz, 2H), 6.73 (s, 1H), 6.36 (dd,  $J = 3.4, 1.8$  Hz, 1H), 6.24 (d,  $J = 3.4$  Hz, 1H), 4.55 (dd,  $J = 14.6, 6.1$  Hz, 1H), 4.15 – 3.99 (m, 3H), 3.93 (dd,  $J = 14.6, 9.8$  Hz, 1H), 2.25 (s, 3H), 1.15 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.0, 153.8, 143.4, 141.9, 139.0, 137.1, 132.9, 132.5, 129.1, 128.4, 128.0, 127.6, 126.9, 125.1, 111.5, 106.6, 61.5, 52.6, 47.8, 21.4, 14.0. IR (KBr):  $\nu$  2925, 2853, 1731, 1630, 1597, 1493, 1350, 1290, 1163, 1096, 912, 808, 739, 709, 691, 654  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{23}\text{NO}_5\text{S}$   $[\text{M}+\text{H}]^+ = 438.1370$ , found = 438.1374.

**Ethyl 4-(thiophen-2-yl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4au)**




The title compound was prepared according to the general procedure to afford **4au** (40.9 mg, 90% yield) as a yellow solid. M.p. 99.8 – 102.2 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.62 – 7.54 (m, 1H), 7.48 – 7.42 (m, 2H), 7.28 – 7.17 (m, 3H), 7.15 (dd, *J* = 5.1, 1.1 Hz, 1H), 7.02 (d, *J* = 8.0 Hz, 2H), 6.93 (dd, *J* = 5.1, 3.6 Hz, 1H), 6.86 (dd, *J* = 3.7, 1.2 Hz, 1H), 6.55 (s, 1H), 4.58 (dd, *J* = 14.5, 5.9 Hz, 1H), 4.17 (ddd, *J* = 9.4, 5.9, 1.1 Hz, 1H), 4.05 – 3.91 (m, 3H), 2.25 (s, 3H), 1.07 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.6, 145.5, 143.5, 138.8, 137.2, 132.9, 132.7, 132.3, 129.3, 128.6, 128.04, 127.96, 127.6, 127.3, 126.9, 124.4, 123.9, 61.4, 52.6, 49.9, 21.4, 13.9. IR (KBr): ν 2979, 2929, 1731, 1597, 1493, 1349, 1290, 1162, 1093, 911, 812, 757, 709, 692, 656 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>26</sub>H<sub>23</sub>NO<sub>4</sub>S<sub>2</sub> [M+H]<sup>+</sup> = 454.1141, found = 454.1139.

**Ethyl 4-(naphthalen-1-yl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4av)**



The title compound was prepared according to the general procedure to afford **4av** (28.9 mg, 58% yield) as a white solid. M.p. 124.8 – 126.3 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81 (dd, *J* = 7.5, 1.9 Hz, 1H), 7.74 (d, *J* = 8.2 Hz, 1H), 7.69 – 7.62 (m, 3H), 7.48 – 7.38 (m, 2H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.31 – 7.24 (m, 5H), 7.24 – 7.18 (m, 1H), 6.88 (br, 1H), 6.43 (s, 1H), 4.61 (dd, *J* = 14.7, 5.2 Hz, 1H), 4.25 (dd, *J* = 9.6, 4.6 Hz, 1H), 3.97 (dd, *J* = 14.6, 10.8 Hz, 1H), 3.57 (q, *J* = 7.1 Hz, 2H), 2.42 (s, 3H), 0.56 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.9, 143.6, 140.0, 139.2, 138.4, 133.7, 132.6, 132.4, 132.3, 129.7, 128.13, 128.06, 127.7, 127.4, 127.2, 126.0, 125.7, 125.6, 124.8, 60.8, 52.1, 51.1, 21.6, 13.3. IR (KBr): ν 2924, 1727, 1630, 1592, 1493, 1350, 1304, 1161, 1094, 802, 778, 709, 691 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>30</sub>H<sub>27</sub>NO<sub>4</sub>S [M+H]<sup>+</sup> = 498.1734, found = 498.1735.


**Ethyl 4-(naphthalen-2-yl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4aw)**



The title compound was prepared according to the general procedure to afford **4aw** (36.8 mg, 74%


yield) as a white solid. M.p. 126.9 – 131.3 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.84 – 7.77 (m, 1H), 7.74 (d, *J* = 8.2 Hz, 1H), 7.69 – 7.61 (m, 3H), 7.48 – 7.39 (m, 2H), 7.35 (t, *J* = 7.7 Hz, 1H), 7.33 – 7.23 (m, 5H), 7.24 – 7.18 (m, 1H), 6.88 (br, 1H), 6.43 (s, 1H), 4.61 (dd, *J* = 14.7, 5.3 Hz, 1H), 4.26 (ddd, *J* = 10.9, 5.4, 2.0 Hz, 1H), 3.97 (dd, *J* = 14.6, 10.8 Hz, 1H), 3.57 (q, *J* = 7.1 Hz, 2H), 2.42 (s, 3H), 0.56 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.9, 143.6, 140.0, 139.2, 138.4, 133.7, 132.6, 132.4, 132.3, 131.2, 129.7, 128.12, 128.05, 127.7, 127.4, 127.2, 126.0, 125.7, 125.6, 124.7, 60.8, 52.1, 51.1, 21.6, 13.3. IR (KBr): ν 2978, 2926, 2854, 1730, 1630, 1493, 1350, 1304, 1162, 1095, 911, 803, 799, 709, 691, 659 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>30</sub>H<sub>27</sub>NO<sub>4</sub>S [M+H]<sup>+</sup> = 498.1734, found = 498.1737.

**Ethyl 4-(quinolin-3-yl)-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ax)**



The title compound was prepared according to the general procedure to afford **4ax** (45.0 mg, 90% yield) as a yellow solid. M.p. 71.6 – 73.4 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.71 (d, *J* = 2.3 Hz, 1H), 8.08 (d, *J* = 8.4 Hz, 1H), 7.82 – 7.75 (m, 2H), 7.71 (ddd, *J* = 8.4, 6.9, 1.4 Hz, 1H), 7.65 (dt, *J* = 7.1, 3.6 Hz, 1H), 7.62 – 7.53 (m, 3H), 7.34 – 7.27 (m, 3H), 7.16 (d, *J* = 8.0 Hz, 2H), 6.50 (d, *J* = 1.6 Hz, 1H), 4.67 (dd, *J* = 14.6, 5.7 Hz, 1H), 4.34 (ddd, *J* = 10.1, 5.8, 1.6 Hz, 1H), 3.96 (dd, *J* = 14.6, 10.0 Hz, 1H), 3.84 (q, *J* = 7.1 Hz, 2H), 2.27 (s, 3H), 0.85 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.0, 149.1, 147.2, 143.7, 138.9, 138.0, 136.4, 134.9, 132.7, 132.6, 132.6, 131.9, 129.6, 129.5, 129.1, 128.9, 128.5, 127.8, 127.7, 127.2, 127.1, 61.3, 51.8, 49.7, 21.4, 13.7. IR (KBr): ν 3054, 2980, 2930, 1731, 1596, 1568, 1349, 1305, 1162, 1093, 910, 814, 753, 709, 692, 655 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>29</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub>S [M+H]<sup>+</sup> = 499.1686, found = 499.1685.


**Ethyl (E)-4-styryl-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ay)**



The title compound was prepared according to the general procedure to afford **4ay** (24.8 mg, 52% yield) as a yellow solid. M.p. 89.3 – 93.8 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.61 – 7.53 (m, 1H), 7.52 – 7.45 (m, 2H), 7.39 – 7.30 (m, 4H), 7.26 – 7.16 (m, 4H), 7.08 (d, *J* = 8.1 Hz, 2H), 6.59 (d, *J* = 16.4 Hz, 1H), 6.45 (d, *J* = 16.4 Hz, 1H), 6.36 (s, 1H), 4.55 (dd, *J* = 14.6, 6.0 Hz, 1H), 4.24 – 4.02 (m, 3H), 3.88 (dd, *J* = 14.6, 10.1 Hz, 1H), 2.24 (s, 3H), 1.20 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR


(101 MHz, CDCl<sub>3</sub>)  $\delta$  171.1, 143.4, 139.4, 137.3, 137.0, 136.9, 132.8, 132.6, 132.2, 129.3, 128.7, 128.5, 128.1, 128.0, 127.7, 127.4, 127.1, 126.4, 61.5, 52.1, 47.6, 21.4, 14.1. **IR** (KBr):  $\nu$  2730, 1727, 1630, 1581, 1493, 1347, 1303, 1161, 1101, 963, 813, 749, 710, 654 cm<sup>-1</sup>; **HRMS** (ESI):  $m/z$  calcd for C<sub>28</sub>H<sub>27</sub>NO<sub>4</sub>S [M+H]<sup>+</sup> = 474.1734, found = 474.1743.

**Ethyl 1-(methylsulfonyl)-4-phenyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ba)**




The title compound was prepared according to the general procedure to afford **4ba** (30.5 mg, 81% yield) as a white solid. M.p. 135.2 – 139.2 °C; **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.68 – 7.61 (m, 1H), 7.47 – 7.41 (m, 2H), 7.40 – 7.27 (m, 6H), 6.79 (s, 1H), 4.39 – 4.27 (m, 2H), 4.13 (td,  $J$  = 10.6, 4.4 Hz, 1H), 3.93 (q,  $J$  = 7.2 Hz, 2H), 2.89 (s, 3H), 0.99 (t,  $J$  = 7.1 Hz, 3H). **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.6, 142.4, 140.1, 138.4, 132.9, 132.5, 130.2, 128.5, 128.3, 127.93, 127.87, 127.7, 126.5, 61.2, 51.2, 50.5, 40.2, 13.7. **IR** (KBr):  $\nu$  3054, 3023, 2980, 2934, 1731, 1630, 1570, 1572, 1493, 1343, 1154, 962, 760, 699 cm<sup>-1</sup>; **HRMS** (ESI):  $m/z$  calcd for C<sub>20</sub>H<sub>21</sub>NO<sub>4</sub>S [M+H]<sup>+</sup> = 372.1264, found = 372.1266.

**Ethyl 1-((4-nitrophenyl)sulfonyl)-4-phenyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4ca)**




The title compound was prepared according to the general procedure to afford **4ca** (32.7 mg, 68% yield) as a yellow solid. M.p. 124.1 – 128.1 °C; **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.16 – 8.09 (m, 2H), 7.78 – 7.71 (m, 2H), 7.67 – 7.59 (m, 1H), 7.42 – 7.31 (m, 2H), 7.30 – 7.23 (m, 3H), 7.23 – 7.17 (m, 1H), 7.09 – 7.02 (m, 2H), 6.25 (s, 1H), 4.65 (dd,  $J$  = 14.2, 5.7 Hz, 1H), 4.20 (dd,  $J$  = 14.2, 8.8 Hz, 1H), 4.09 (ddd,  $J$  = 8.8, 5.7, 1.0 Hz, 1H), 3.84 (qd,  $J$  = 7.1, 1.9 Hz, 2H), 0.89 (t,  $J$  = 7.1 Hz, 3H). **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.1, 149.8, 145.8, 141.1, 140.0, 137.1, 134.1, 131.9, 129.7, 129.3, 128.6, 128.5, 128.4, 128.3, 128.1, 126.0, 123.9, 61.3, 53.8, 48.8, 13.7. **IR** (KBr):  $\nu$  2978, 2928, 2869, 1728, 1630, 1605, 1530, 1349, 1306, 1168, 1095, 855, 766, 738, 698, 610 cm<sup>-1</sup>; **HRMS** (ESI):  $m/z$  calcd for C<sub>25</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>S [M+H]<sup>+</sup> = 479.1271, found = 479.1276.

**Ethyl 1-((4-methoxyphenyl)sulfonyl)-4-phenyl-2,3-dihydro-1H-benzo[b]azepine-3-carboxylate (4da)**




The title compound was prepared according to the general procedure to afford **4da** (37.6 mg, 81% yield) as a white solid. M.p. 85.2 – 86.9 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66 – 7.60 (m, 1H), 7.59 – 7.53 (m, 2H), 7.31 – 7.23 (m, 5H), 7.23 – 7.17 (m, 1H), 7.16 – 7.11 (m, 2H), 6.82 – 6.75 (m, 2H), 6.35 (d, *J* = 1.5 Hz, 1H), 4.59 (dd, *J* = 14.5, 5.5 Hz, 1H), 4.20 (ddd, *J* = 9.8, 5.6, 1.5 Hz, 1H), 3.94 (dd, *J* = 14.5, 9.7 Hz, 1H), 3.85 (q, *J* = 7.1 Hz, 2H), 3.74 (s, 3H), 0.89 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.4, 162.8, 142.1, 139.7, 138.6, 133.2, 132.3, 132.2, 129.8, 129.2, 128.9, 128.1, 127.9, 127.6, 127.5, 126.5, 113.9, 61.0, 55.5, 52.0, 49.6, 13.7. IR (KBr): ν 2928, 2842, 1728, 1630, 1595, 1496, 1349, 1305, 1157, 1093, 908, 832, 805, 767, 697 cm<sup>-1</sup>; HRMS (ESI): *m/z* calcd for C<sub>26</sub>H<sub>25</sub>NO<sub>5</sub>S [M+H]<sup>+</sup> = 479.1271, found = 479.1276.

## H. Gram scale synthesis of 4aa



To a dried 100 mL round-bottomed flask with a magnetic stirring bar was added **1a** (1.2 g, 4.0 mmol, 1.0 equiv.), **2a** (1 g, 4.0 mmol, 1.0 equiv.), followed by the addition of toluene (40 mL). Allow the solid to dissolve completely, PCy<sub>3</sub> (336 mg, 30 mol%) was added at room temperature. Then the reaction mixture was stirred at 80 °C for 3 h and monitored by TLC. The reaction solution was concentrated under reduced pressure and then purified directly by column chromatography directly on silica gel with PE/EA as eluent to afford **4aa** (1.11 g, 62% yield).

## I. Transformation of the product 4aa



m-Chloroperbenzoic acid (170 mg, 1.0 mmol, 2.0 equiv.) was added to a solution of **4aa** (220 mg, 0.5 mmol, 1.0 equiv.) in  $\text{CH}_2\text{Cl}_2$  (5 mL), and the mixture was stirred at room temperature for 5 days and monitored by TLC.  $\text{CH}_2\text{Cl}_2$  was then added, and the solution was washed with NaOH (2 N), dried with anhydrous  $\text{Na}_2\text{SO}_4$ , and concentrated. The residue was purified by column chromatography directly on silica gel with PE/EA as eluent to give the targeted products **5** (130 mg, 57% yield) as a white solid. M.p. 158.2 – 159.2 °C;  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.55 (dd,  $J = 7.5, 1.8$  Hz, 1H), 7.52 – 7.46 (m, 2H), 7.43 – 7.27 (m, 8H), 7.05 (d,  $J = 8.0$  Hz, 2H), 4.84 (t,  $J = 13.0$  Hz, 1H), 4.03 – 3.87 (m, 2H), 3.74 (dd,  $J = 13.4, 6.5$  Hz, 1H), 3.53 (s, 1H), 2.59 (dd,  $J = 12.7, 6.4$  Hz, 1H), 2.33 (s, 3H), 0.95 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  169.7, 143.6, 136.9, 136.7, 135.4, 134.4, 130.4, 129.8, 129.6, 129.5, 129.3, 128.3, 128.2, 127.4, 126.1, 61.2, 60.9, 60.4, 49.6, 47.4, 21.5, 13.8. IR (KBr):  $\nu$  3036, 2925, 1728, 1630, 1598, 1493, 1348, 1163, 1115, 1092, 1064, 938, 903, 815, 760, 710, 661  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$  calcd for  $\text{C}_{26}\text{H}_{26}\text{NO}_5\text{S}$   $[\text{M}+\text{H}]^+ = 464.1526$ , found = 464.1530.

## J. X-Ray crystallographic analysis




Figure 1. X-ray structure of **3ca**

The title compound was recrystallized from hexane/DCM, by slow evaporation of solvent.

Table 2. Crystal data and structure refinement for **3ca** (CCDC 2269752)

Empirical formula	C <sub>25</sub> H <sub>22</sub> N <sub>2</sub> O <sub>6</sub> S	
Formula weight	478.50	
Temperature	296 K	
Wavelength	0.71073 Å	
Crystal system	monoclinic	
Space group	P 2 <sub>1</sub> /c	
Unit cell dimensions	a = 14.452(3) Å	α = 90.
	b = 17.525(4) Å	β = 108.347(3).
	c = 9.769(2) Å	γ = 90.
Volume	2348.4(9) Å <sup>3</sup>	
Z	4	
Density (calculated)	1.353 Mg/m <sup>3</sup>	
Absorption coefficient	0.182 mm <sup>-1</sup>	
F(000)	1000	
Crystal size	0.210 x 0.180 x 0.170 mm <sup>3</sup>	
Theta range for data collection	1.485 to 27.530°.	
Index ranges	-18 ≤ h ≤ 18, -19 ≤ k ≤ 22, -12 ≤ l ≤ 11	
Reflections collected	14426	
Independent reflections	5381 [R(int) = 0.0312]	
Completeness to theta = 25.242°	99.9 %	
Refinement method	Full-matrix least-squares on F <sup>2</sup>	
Data / restraints / parameters	5381 / 44 / 339	
Goodness-of-fit on F <sup>2</sup>	1.133	
Final R indices [I > 2σ(I)]	R1 = 0.0527, wR2 = 0.1642	
R indices (all data)	R1 = 0.0660, wR2 = 0.1795	
Largest diff. peak and hole	0.470 and -0.467 e.Å <sup>-3</sup>	






Figure 2. X-ray structure of **4aa**

The title compound was recrystallized from hexane/DCM, by slow evaporation of solvent.

Table 3. Crystal data and structure refinement for **4aa** (CCDC 2269753)

Empirical formula	C <sub>26</sub> H <sub>25</sub> N O <sub>4</sub> S	
Formula weight	447.53	
Temperature	296K	
Wavelength	0.71073 Å	
Crystal system	triclinic	
Space group	P -1	
Unit cell dimensions	a = 10.622(5)Å	α = 63.485(6).
	b = 11.052(6)Å	β = 68.532(6).
	c = 12.153(6)Å	γ = 70.726(6)
	77.611(4).	
Volume	1164.0(10) Å <sup>3</sup>	
Z	2	
Density (calculated)	1.277 Mg/m <sup>3</sup>	
Absorption coefficient	0.171 mm <sup>-1</sup>	
F(000)	472	
Crystal size	0.22 x 0.20 x 0.19 mm <sup>3</sup>	
Theta range for data collection	1.939 to 27.581°.	
Index ranges	-13 ≤ h ≤ 12, -14 ≤ k ≤ 13, -14 ≤ l ≤ 15	
Reflections collected	7258	
Independent reflections	5202 [R(int) = 0.0159]	
Completeness to theta = 25.242°	98.7 %	
Refinement method	Full-matrix least-squares on F <sup>2</sup>	
Data / restraints / parameters	5202 / 0 / 291	
Goodness-of-fit on F <sup>2</sup>	1.077	
Final R indices [I > 2σ(I)]	R1 = 0.0461, wR2 = 0.1446	
R indices (all data)	R1 = 0.0600, wR2 = 0.1581	
Largest diff. peak and hole	0.287 and -0.382 e.Å <sup>-3</sup>	




Figure 3. X-ray structure of **5**

The title compound was recrystallized from hexane/DCM, by slow evaporation of solvent.



Table 3. Crystal data and structure refinement for **5** (CCDC 2377466)



Empirical formula	C <sub>26</sub> H <sub>25</sub> N O <sub>5</sub> S	
Formula weight	463.53	
Temperature	293K	
Wavelength	1.54184 Å	
Crystal system	monoclinic	
Space group	P 1 2 <sub>1</sub> /c 1	
Unit cell dimensions	a = 10.5226(3) Å	α = 90.
	b = 8.5185(3) Å	β = 91.414(3).
	c = 25.6829(6) Å	γ = 90.
Volume	2301.43(12) Å <sup>3</sup>	
Z	4	
Density (calculated)	1.338 Mg/m <sup>3</sup>	
Absorption coefficient	0.171 mm <sup>-1</sup>	
F(000)	976.0	
Crystal size	0.2 x 0.2 x 0.1 mm <sup>3</sup>	
Theta range for data collection	3.443 to 74.620°.	
Index ranges	-13 ≤ h ≤ 12, -10 ≤ k ≤ 10, -31 ≤ l ≤ 28	
Reflections collected	21772	
Independent reflections	4571 [R(int) = 0.0439]	
Completeness to theta = 67.684°	97 %	
Refinement method	Full-matrix least-squares on F <sup>2</sup>	
Data / restraints / parameters	5202/ 24 /311	
Goodness-of-fit on F <sup>2</sup>	1.078	
Final R indices [I > 2σ(I)]	R1 = 0.0564, wR2 = 0.1632	
R indices (all data)	R1 = 0.0639, wR2 = 0.1738	
Largest diff. peak and hole	0.816 and -0.573 e.Å <sup>-3</sup>	



## **K. Reference**



- [1] R. Manzano, A. Romaniega, L. Prieto, E. Díaz, E. Reyes, U. Uria, L. Carrillo, and J. L. Vicario, *Org. Lett.*, **2020**, 22, 4721–4725.



# L. NMR Spectra





























































-113.30




































































8.27  
8.26  
8.26  
8.25  
8.25  
8.24  
8.24  
8.23  
7.89  
7.88  
7.87  
7.86  
7.85  
7.38  
7.37  
7.36  
7.35  
7.23  
7.23  
7.23  
7.21  
7.20  
7.19  
7.18  
7.18  
7.17  
7.17  
7.16  
7.16  
7.15  
7.15  
7.14  
7.14  
7.13  
7.10  
6.98  
6.97  
6.96  
6.94  
6.94  
6.93  
6.93  
6.92  
6.91  
6.91  
6.90  
6.88  
6.88  
6.88  
6.86  
6.86  
6.86  
6.41  
6.24  
6.24  
5.57  
5.57  
4.19  
4.17  
4.15  
4.14  
4.13  
4.13  
4.12  
4.118








166.45  
150.11  
145.32  
142.91  
142.44  
137.13  
132.87  
130.76  
130.56  
128.80  
128.52  
128.46  
128.16  
127.53  
125.91  
124.99  
124.20  
123.37  
61.20  
13.95















































-114.44

